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Altered levels of SOX2, and its associated protein Musashi2,
disrupt critical cell functions in cancer and embryonic stem cells

Erin Lynn Wuebben, Ph.D.
University of Nebraska, 2016
Advisor: Angie Rizzino, Ph.D.
The transcription factor SOX2 is widely recognized for its critical roles during
mammalian embryogenesis. SOX2 has also been examined in cancer; and it has been implicated
in the growth, tumorigenicity, drug resistance, or metastasis of over 20 different cancers,
including cancers of the brain and pancreas. Thus, we hypothesized that SOX2 is a major player
in cancer and may be a potential therapeutic target; however, the effects of SOX2 on the many
facets of human cancer have only begun to be explored. Recently, efforts to understand the
mechanisms by which SOX2 mediates its effects have explored SOX2 protein-protein interaction
landscapes in a number of cellular systems. Previous studies in our laboratory identified proteins,
like the RNA-binding protein Musashi2 (Msi2), which interact with SOX2 in multiple cell types,
including embryonic stem cells and brain tumor cells. We hypothesized that proteins that interact
with SOX2 in multiple cell types are likely to be necessary for the continued growth and function
of these cells. The studies presented in this dissertation demonstrate that ESC require Msi2 to
maintain self-renewal and pluripotency; and that MSI2 is also required to support the growth and
survival of DAOY, U87, and U118 brain tumor cell lines. This dissertation also examined the
roles of SOX2 in pancreatic adenocarcinoma (PDAC). Multiple PDAC cell lines were engineered
for either inducible overexpression of SOX2 or inducible knockdown of SOX2. Through in vitro
growth and tumorigenicity studies with these inducible PDAC cell lines, we determined that
SOX2 functions as a biphasic molecular rheostat in PDAC. Furthermore, we determined that
inducible elevation of SOX2 in PDAC cells reduces the growth inhibitory effects of MEK and
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AKT inhibitors, while the inducible knockdown of SOX2 enhanced growth inhibition in the
presence of these inhibitors. Altogether, the work presented in this dissertation extends and
strengthens our knowledge of SOX2 and its function as a master regulator in multiple cell types,
and provides useful platforms for the continued study of these highly deadly malignancies.
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CHAPTER 1:

Introduction
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1.1

Introduction
The transcription factor SOX2 is widely recognized for its critical roles during

mammalian embryogenesis. Although Sox2 was first shown to regulate the transcription of FGF4
in mouse embryonal carcinoma cells [1], its importance was firmly established with the discovery
that knocking out both alleles of SOX2 results in embryonic lethality in mice. SOX2 null
embryos reach the blastocyst stage, but do not survive after implantation [2]. Shortly thereafter,
knocking down Sox2 in mouse embryonic stem cells (ESC) was shown to disrupt their selfrenewal and induce differentiation [3]. One year later interest in Sox2 rose dramatically with the
paradigm shifting discovery by Takahashi and Yamanaka demonstrating conversion of mouse
embryonic fibroblasts into induced pluripotent stem (iPS) cells by the introduction of Sox2 along
with Oct4, Klf4, and cMyc [4].
The excitement surrounding the key roles of SOX2 in ESC and iPS cells, which are
themselves tumorigenic, soon led to the search for SOX2 in cancer. Within a few years following
the discovery of iPS cells, numerous reports of SOX2 expression in human cancer had already
appeared. This soon turned into an avalanche of studies examining SOX2 in human cancer. The
search terms SOX2 and cancer generate over 1600 hits in the PubMed database since 2006.
During that period, SOX2 has been implicated in growth, tumorigenicity, drug resistance, and
metastasis in over 20 different cancers, including cancers of the ovary, lung, skin, brain, breast,
prostate, and pancreas. In the majority of these cancers, SOX2 has been reported to have
increased expression or gene amplification in tumor tissue; however, the effects of SOX2 on
tumorigenicity, prognosis, and drug resistance in human cancer have only begun to be explored.
Nonetheless, it is evident from the impressive body of work published thus far that SOX2 is a
major player in cancer and a potential therapeutic target.
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1.2

Sox2 Gene Structure and Regulation
1.2.1

Transcriptional Regulation of Sox2

The transcriptional regulation of Sox2 has been extensively studied. However, it is
evident that there is much more to learn about how this gene is regulated at the transcriptional
level. Sox2 is a member of the SRY-related gene family, each member of which contains a wellconserved high mobility group domain (HMG box, 79 amino acids), which mediates its binding
to DNA. The Sox2 gene, a single exon, in mammals, as well as birds, is located within a gene
desert (a large genomic region largely devoid of other protein coding genes). Analysis of a 200
kilobase (kb) region of the chicken gene that surrounds the Sox2 single exon identified at least 27
distinct enhancers that are transcriptionally active for the regulation of Sox2 during neuro-sensory
development in the chicken [5]. Eleven of the enhancers are distributed fairly evenly over a 97 kb
region located upstream of the coding region of the Sox2 gene, and 16 enhancers are fairly evenly
distributed over a 110 kb region downstream of the coding region of the Sox2 gene. The large
majority of the enhancers identified in the chicken genome are located in regions that are
conserved in mammals. Thus, it is likely that the mammalian Sox2 gene is also transcriptionally
regulated by a large number of distinct distal enhancers during different stages of development.
However, far more work will be needed to define the regulatory regions of mammalian Sox2 gene
that are active in specific cell types. As discussed below, only three enhancers have been
identified as functionally active in mammalian cells, one of which is located ~100 kb downstream
of the Sox2 gene.
In mammalian cells, transcriptional regulation of the Sox2 gene, including the enhancers
that drive Sox2 expression, has been primarily studied in mouse ESC. In addition to the basal
promoter of the Sox2 gene [6], early studies identified two enhancers, Sox2 regulatory region 1
(SRR1) and SRR2, which influence the activity of the Sox2 promoter. SRR1 is located ~ 4kb
upstream of the Sox2 transcription start site; whereas, SRR2 is located ~2.5 kb downstream of the
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3’ end of the Sox2 coding region [7]. Although SRR1 has been shown to be active in
promoter/reporter gene constructs expressed in ESC, its impact on the expression of Sox2 in ESC
is minimal when SRR1 is deleted from the endogenous Sox2 gene [8]. However, deleting a region
-5.7 to -3.3 kb upstream of the Sox2 transcription start site, which contains SRR1, abolished
expression of SOX2 in telencephalic neural stem cells and precursors during murine development
[9, 10]. SRR2 is not only active in mouse ESC; it has been used to isolate human iPS cells [11].
For these studies, the SRR2 enhancer was multimerized (4 tandem repeats) and inserted into a
lentiviral vectors which drives the expression of enhanced green fluorescence protein (EGFP) via
a minimal promoter only when SRR2 is active. Subsequently, and discussed further below, this
lentiviral vector which drives EGFP was shown to be active in breast cancer cells [12]; and
isolation of the subset of EGFP-expressing breast tumor cells were shown to exhibit enhanced
tumorigenic potential, but only when NOD/SCID mice were engrafted with a large number of
cells [13].
Several studies have examined the transcriptional machinery that regulates the activity of
SRR2. The sequence of SRR2 contains adjacent HMG and POU motifs (referred to as an
HMG/POU cassette) that have been shown to be essential for the activity of SRR2 in ESC and
bind Sox2 and Oct4 in ESC [7]. These studies led to the conclusion that Sox2 in combination
with Oct4 contributes to the transcription of Sox2 in ESC. However, this may not be the only role
of SRR2 in the transcription of Sox2. In fact, several recent studies lead us to suggest that a major
role of SRR2 may be to repress, not activate, Sox2 transcription, especially during differentiation.
First, as in the case of SRR1, deletion of SRR2 from the endogenous Sox2 gene did not
significantly reduce Sox2 expression in ESC [8]. Even more suggestive of a repressive role for
SRR2 is the finding that SRR2 is able to bind transcriptional repressors, such as p21, p27Kip1, and
the p130/E2F4-SIN3A repressor complex, in neural stem cells and iPS cells undergoing
differentiation [14, 15]. Consistent with these findings, Sox2 mRNA is elevated in Rb (p105) null
and p130 (retinoblastoma family member) null mouse embryonic fibroblasts, and it is elevated in
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the pituitary tissue of Rb heterozygous mice [16]. Moreover, in pituitary tumors, loss of Rb or
p130 has been linked to a defect in the repression of Sox2 expression [16]. Given the roles of p21,
p27Kip1, and Rb proteins in the G1 cell cycle check point, Sox2 expression may be reduced in G1
phase of the cell cycle. Future studies should consider whether SOX2 expression is cell cycle
regulated.
In ESC, a critical enhancer region (referred to as SCR – Sox2 control region) required for
Sox2 transcription is located ~100 kb downstream of the Sox2 gene [8]. Previous studies had
predicted 10 enhancers surrounding the Sox2 gene, including two that overlapped SRR1 and
SRR2. When tested in promoter/reporter gene constructs, three of the 10 putative enhancers,
which are located 18, 107, and 111 kb downstream of the Sox2 gene, were found to drive the
expression of the reporter gene more potently than SRR1 and SRR2 in ESC. Importantly, more
definitive results were obtained by generating deletions of these enhancers in one allele of the
Sox2 gene using clustered regularly interspaced short palindromic repeats (CRISPR) based gene
editing [8]. Deletion of SRR1, SRR2, or the enhancer located 18 kb downstream of Sox2 did not
affect the expression of the targeted allele. In strong contrast, deletion of the SCR reduced
expression in the targeted allele. (For these studies, expression of the targeted and non-targeted
alleles was monitored separately by PCR in a heterozygous ESC line containing one allele from
mouse strain Mus musculus and one allele from Mus castaneus.) Consequently, targeting one
Sox2 allele in ESC did not impact the maintenance of pluripotent ESC, due to upregulation of the
non-targeted Sox2 allele. This finding and earlier studies involving Sox2 overexpression in ESC
(see below) indicate that Sox2 influences its own expression in ESC by a feedback loop. In the
future, it will be important to determine whether the SCR that is active in ESC, is also active in
other SOX2 expressing cells, in particular SOX2-positive tumor cells. Thus far, only SRR2 has
been reported to be active in SOX2-positive tumor cells.
Sox2 not only positively influences Sox2 expression in ESC when it is under expressed,
it has the opposite effect when Sox2 is overexpressed in ESC. As discussed later, ESC engineered
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for inducible overexpression of Sox2 undergo differentiation when Sox2 is elevated by 2-fold or
more. Interestingly, overexpression of exogenous Flag-tagged Sox2 in ESC reduces endogenous
Sox2 expression at the protein level [17] and at the transcriptional level [18]. Specifically, it was
determined that elevation of exogenous Sox2 activated a negative feedback loop mediated at least
in part by increased phosphorylation of AKT and one of its downstream targets, FoxO1, which
regulates transcription of Sox2 [18]. When FoxO1 is phosphorylated, it translocates out of the
nucleus, thus reducing Sox2 transcription. Thus in ESC, Sox2 can regulate its own expression at
the transcriptional levels by both positive and negative feedback loops when Sox2 expression is
too low and when Sox2 expression is too high, respectively. While it is evident that the
transcriptional regulation of SOX2 has been extensively studied, there is far more to learn how
this gene is regulated at the transcriptional level.

1.2.2

MicroRNAs and SOX2 Expression

A large body of data has implicated microRNAs (miRs) in the function of normal
embryonic and adult cells, as well diseased tissues, in particular cancer. More than 10 years ago,
ChIP-Chip studies conducted by Boyer et al determined that SOX2 associates with the regulatory
regions of many miR genes in human ESC [19]. This finding was extended by ChIP-seq analysis
of Sox2 chromatin binding in mouse ESC [20]. More recently, Fang et al determined by ChIP-seq
that SOX2 is bound to over 100 miR genes in a glioblastoma cell line [21]. Further study is
expected to show that SOX2 regulates the transcription of a large number of miRs in a wide
variety of SOX2-positive tumors. However, the specific miR genes regulated by SOX2 are
expected to differ widely between tumor cell types due to differences in their transcriptional
circuitries.
In addition to the regulation of miRs by SOX2, there is a growing list of miRs that are
capable of regulating SOX2 at the post-transcriptional level. In the case of cancer, at least 18
miRs have been reported to regulate SOX2 expression in tumor cell lines (Table 1.1), include

7

8

NT/2). Of these, miR-145 has been implicated directly or indirectly in ESC and at least seven
cancers, glioblastoma, prostate cancer, non-small cell lung carcinoma, Ewing sarcoma,
hepatocellular carcinoma, pancreatic adenocarcinoma, and urothelial carcinoma [22-29].
Interestingly, in glioblastoma, SOX2 and miR145 have been reported to form a negative feedback
loop with one another. In this tumor, Sox2 can associate with the gene regulatory regions of
miR145, where it is believed to repress miR145 transcription; whereas miR145 reduces the
expression of SOX2 by interfering with its translation [21]. In colorectal cancer, miR-200c and
SOX2 also appear to regulate one another by a negative feedback loop [30]. With one notable
exception [31], SOX2-targeting miRs are associated with downregulation of SOX2.
The association of SOX2 and miRs in specific cancers has been inferred predominately
from the correlation between elevated SOX2 expression and low miR expression. In most studies,
this association is supported by two additional lines of evidence, down regulation of SOX2 when
the miR in question is ectopically elevated in tumor cell lines, and down regulation of a reporter
gene construct, typically luciferase, containing a portion of the SOX2 3’ untranslated region
(UTR) when the miR is ectopically expressed in tumor cell lines (Table 1.1).
For some cancers only a single miR has been implicated thus far in the regulation of
SOX2. For example, when miR-30a is upregulated in nasopharyngeal carcinoma cells it appears
to be capable of reducing SOX2 protein levels by targeting the 3’ UTR of SOX2 mRNA [32].
However, it is likely that SOX2 can be regulated by several miRs in the same cell type. In gastric
carcinoma, prostate cancer, and colorectal cancer, more than one miR has been implicated in the
regulation of SOX2 (Table 1.1). In prostate cancer, SOX2 expression is associated with low
expression of both miR-145 and miR-34b [24, 33]. However, unlike miR-145, which has been
shown to target the 3’ UTR of the Sox2 transcript [22], it is unclear whether miR-34b targets
SOX2 directly. In the case of colorectal cancer, miR-200c, miR-638, miR-450-5p, and miR-429
have been reported to regulate SOX2, but with different outcomes (Table 1.1). Lu et al reported
that miR-200c, which is expressed at lower levels in colorectal specimens and highly metastatic
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colorectal cell lines, exhibits an inverse relationship with SOX2 [30]. Similarly, Ma et al has also
shown that miR-638, which is expressed at a lower level in colorectal tumors than adjacent nontumorigenic tissue, is able to target SOX2 [34], and Jin et al reported that miR-450-5p, which is
downregulated in recurrent colorectal cancer, is capable of downregulating SOX2 [35]. In
contrast, Li et al reported that higher levels of miR-429 and lower levels of SOX2 mRNA in
colorectal cancer are correlated with poor survival after surgery [36]. Interestingly, these
investigators argued that high miR-429 expression exerts its anti-apoptotic function by
downregulating SOX2. However, this is inconsistent with the apparent oncogenic role of SOX2
in a subgroup of in colorectal cancer patients. In this regard, Lundberg et al reported that SOX2positive colorectal cancer patients do not survive as long as SOX2-negative colorectal cancer
patients; and this differential is larger for patients with BRAFV600E mutations who survive for
substantially shorter periods than those who are SOX2-positive, but lack the BRAF mutation
[37]. Going forward, it will be important to determine whether the levels of miR-429 are lower in
colorectal cancer patients with BRAFV600E mutations. One of the mechanisms by which miR429 promotes colorectal cancer may be to help maintain SOX2 within optimal levels in the
BRAFV600E-mutant subgroup of colorectal tumors, which is discussed in greater detail later.
More than one miR has also been reported to target SOX2 in gastric carcinoma. For both
miRs, high miR expression is associated with low SOX2 expression. Li et al reported that miR371-5p, which is elevated in gastric carcinoma compared to adjacent normal tissue, targets SOX2
[38]. In addition, these investigators reported that miR-371-5p downregulated a luciferase
reporter gene construct containing a short sequence from the SOX2 3’ UTR; whereas blocking
expression of this miR in gastric tumor cell line increased SOX2 expression and cell proliferation
in vitro. A similar conclusion was reached for miR-126. Otsubo et al reported that transiently
elevating miR-126 in gastric cancer cell lines decreased SOX2 and increased cell proliferation in
vitro [39]. They also demonstrated that miR-126 reduced the expression of a luciferase reporter
gene containing regions taken from the SOX2 3’ UTR. Furthermore, these investigators reported
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low SOX2 expression and elevated miR-126 in some gastric tumor specimens, but the results
reported do not appear to show a clear pattern. Although, elevated miR-126 expression and low
SOX2 expression was observed in several gastric cancer tumor specimens, low miR-126
expression was accompanied by low SOX2 expression in several other gastric tumor specimens.
Thus, a larger number of tumors specimens will need to be evaluated to resolve the relationship
between miR-126 and SOX2. In addition, the relationship between miR-126, SOX2, and patient
survival remains to be determined. As expanded on below, high SOX2 in gastric cancer has been
reported to be associated with longer patient survival [40-42]. Interestingly, there are reports that
miR-126 can act as a tumor suppressor in other types of cancer. For example, Yang et al and
Zhao et al reported that miR-126 behaves as a tumor suppressor in osteosarcoma and
hepatocellular carcinoma, respectively, by targeting SOX2 [43, 44]. Additionally, Hamada et al
reported that loss of mR-126 expression is observed in invasive pancreatic ductal adenocarcinoma
[45].
Although miRs are recognized as important regulators of SOX2 expression, two
important issues need to be considered. First, unless the cell of origin and its expression of miRs
have been determined, it remains to be determined whether the miR in question and its putative
loss during tumor progression did in fact contribute to elevated SOX2 expression. Second, the full
spectrum of SOX2 targeting miRs is likely to be far greater than those already identified.

1.2.3

Long Noncoding RNAs and SOX2 Expression

In addition to miRs, several long noncoding RNAs (lncRNAs) have been reported to
influence the levels of SOX2 in tumor cells. LncRNAs are a class of RNAs that are greater than
200 nucleotides that lack protein-coding sequences. They are transcribed by RNA polymerase II
and they are spliced, 5’ capped, and 3’ polyadenylated. The human genome contains several
thousand lncRNAs, and there is growing evidence that many play major roles in gene regulation
by influencing chromatin structure, gene transcription, and processing of mRNA [46]. More
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recently, several lncRNAs have been implicated in the regulation of SOX2 expression and its
transcriptional activity. The first direct link between SOX2 and lncRNAs was the discovery that
the single exon SOX2 gene is embedded within an intron of a multi-exon lncRNA gene known as
SOX2 overlapping transcript (SOX2OT, also known as non-protein-coding RNA 43) [47]. Like
SOX2 itself, SOX2OT orthologues are expressed widely in other vertebrates, including in mouse,
chicken, and zebrafish. SOX2 and SOX2OT are each transcribed in the same direction. SOX2OT is
reported to possess at least 10 exons with up to four different transcription start sites. Through use
of alternative transcription start sites and alternative splicing at least 8 splice variants of SOX2OT
can be generated [48, 49].
SOX2 and SOX2OT have been shown to be co-expressed in ESC, as well as breast, lung,
brain, and esophageal tumors [50-54]. In each of these cancers, more than one splice variant is
expressed, and the splice variants expressed differ between different cancers. SOX2 and SOX2OT
are also likely to be co-expressed in hepatocellular carcinoma. Separate studies have reported that
expression of SOX2 and SOX2OT in hepatocellular carcinoma is each associated with poor
prognosis [55, 56]. Although the mechanistic relationship between SOX2 expression and
SOX2OT remains to be determined, several studies support the conclusion that SOX2OT lncRNA
contributes to the expression of SOX2. Knockdown of SOX2OT by small interfering RNA
(siRNA) in the lung adenocarcinoma cell line A549 reduced the expression of SOX2 transcripts
[53]. Conversely, forced overexpression of SOX2OT in the breast tumor cell line MDA-MB-231
increased the expression of SOX2 transcripts and protein [51]. Intriguingly, SOX2 and SOX2OT
expression may both be related by at least one miR. miR-211 has been reported to target the same
sequence in transcripts of SOX2OT and SOX2 and lead to their downregulation when miR-211 is
overexpressed in the human embryonal carcinoma cell line NT-2 [57].
In addition to SOX2OT, several other lncRNAs have been directly implicated in the
expression of SOX2. The lncRNA TUNA (Tcl1 Upstream Neuron-Associated), which can form a
complex with three RNA-binding proteins, has been shown by performing chromatin isolation via

12

RNA purification (ChIRP) to associate with the Sox2 promoter in mouse ESC [58]. Furthermore,
knockdown of TUNA by small hairpin RNA (shRNA) reduced the expression of Sox2 and led to
the differentiation of mouse ESC. Interestingly, TUNA and Sox2 are also co-expressed in the
brain [58]. Thus, it will be interesting to determine whether TUNA is expressed in glioblastoma
and medulloblastoma and other SOX2-positive tumors, where it may also contribute to SOX2
expression. However, further study will be needed to determine how TUNA influences SOX2
expression. The lncRNA MALAT1 (Metastasis-Associated Lung Adenocarcinoma Transcript 1)
also appears to influence the expression of SOX2. MALAT1 has been shown to be expressed in
the glioma tumor cell line SHG139S and in two pancreatic tumor cell lines, AsPC1 and CFPAC-1
[59, 60]. Knockdown of MALAT1 in each of these tumor cell lines reduced the expression of
SOX2. However, it is unclear whether the effect of MALAT1 on SOX2 in these tumor cells is
direct or indirect. Equally interesting is the report that lncRNA RoR supports SOX2 expression by
functioning as a miRNA sponge. Specifically, RoR helps maintain SOX2 expression by serving
as an RNA decoy that competes for miRs (e.g. miR145) that target SOX2 expression [61].
LncRNAs also appear to regulate the transcriptional activity of SOX2. The lncRNA
RMST (RhabdoMyoSarcoma 2-associated Transcript) has been reported to coregulate Sox2 target
genes during neurogenesis [62]. RMST interacts physically with SOX2 and promotes the binding
of SOX2 to the regulatory regions of neurogenic transcription factors. Impressively, knockdown
of RMST reduces SOX2 association with approximately half of its chromatin binding sites [62].
Although RMST appears to enhance the transcriptional activity of SOX2, at least one lncRNA,
MEG3 (Maternally Expressed Gene 3) that also physically associates with SOX2, can interfere
with its action. Knockdown of MEG3 has been reported to increase the association of SOX2 with
the BMP4 gene and decrease the transcription of this gene [63]. Thus far, the domains of SOX2
that associate with these lncRNA have not been determined, nor has it been determined how they
influence the transcriptional activity of SOX2. Going forward, it will be interesting to determine
whether RMST and MEG3 are commonly expressed in SOX2-positive tumors, including
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glioblastoma and medulloblastoma. Moreover, MEG3 has been shown to be expressed in
pancreatic tumor cell lines, where its knockdown led to a reduction in cell number in vitro [64].
Thus, it will be interesting to determine whether knockdown of MEG3 alters the function of
SOX2 in pancreatic tumor cells.

1.2.4

Post-translational Modifications of SOX2

Another important mechanism used to regulate SOX2, including its transcriptional
activity, nuclear localization, and stability, is through its post-translational modifications. As
discussed in this section, Sox2 is regulated at the post-translational level by a wide range of
modifications, including phosphorylation, glycosylation, sumoylation, methylation,
ubiquitination, and acetylation. Thus far, nearly all reports of SOX2 post-translational
modifications have been conducted with mouse pluripotent stem cells and mostly with ESC. In
the future, it will be important to characterize the post-translational modifications of SOX2 in
tumor cells. However, at least one study has described a SOX2 post-translational modification
(phosphorylation) in human lung squamous cell carcinoma cells [65]. For the purposes of clarity,
and to avoid confusion, the reader is reminded that human SOX2 and mouse Sox2 differ in length
by 2 amino acids: 317 amino acids and 319 amino acids, respectively due to a two amino acid
insertion beginning at residue 23 in mouse Sox2 (Figure 1.1).
The most common and diverse post-translational modification reported for Sox2 is
phosphorylation. Sox2 phosphorylation influences its transcriptional activity and its stability.
Studies by several research teams have shown that Sox2 can be phosphorylated in vivo on at least
6 serine residues (mouse S39, S83, S248, S251, S252, S253) and two threonine resides (mouse
Sox2 T118 and human SOX2 T118) (Figure 1.1). Sox2 has also been reported to be
phosphorylated when Sox2 is ectopically expressed in 293T cells, which express little if any
endogenous SOX2 [66]. It remains to be determined whether these tyrosine residues are

14

15

phosphorylated in cells that endogenously express SOX2. The kinases responsible for serine
phosphorylation of SOX2 have only begun to be determined. For example, Cdk2 can
phosphorylate both S39 and S253 in vitro [66]. Modifying both serine residues by conversion to
alanine (S39A, S253A) reduces the ability of mutant Sox2 to reprogram somatic cells into iPS
cells. Surprisingly, even though S39 and S253 are phosphorylated in mouse ESC, and most
highly phosphorylated during mitosis, a mutant form of Sox2 (S39A/S253A) is able support the
self-renewal of mouse ESC when endogenous Sox2 is depleted [66]. It is possible that at different
levels of Sox2, phosphorylation of theses serine residues is dispensable.
Serine S248 of mouse Sox2 has been reported to be phosphorylated in mouse ESC.
Phosphorylation of this serine is likely to have a significant role in the function of Sox2, because
this serine, along with T258 in mouse Sox2 (see below) can also be modified by OGlcNAcylation [67, 68]. Studies conducted thus far suggest that modification of S248 in mouse
Sox2 may alter the transcriptional activity of Sox2, but further work will be needed to properly
dissect the impact of phosphorylation and O-GlcNAcylation of Sox2 S248. Similar to this serine
residue, the serine triplet S249-S250-S251 in human SOX2 appears to regulate another posttranslational modification, sumoylation. Human SOX2 has been shown to be sumoylated on
K245 and K247 in mouse Sox2 [69, 70]. Importantly, sumoylation of K245 is abolished in the
SOX2 mutant (S249A-S250A-S251A) [69]. Thus, phosphorylation of one or more serine residues
in the triplet appears to serve as a priming step in the subsequent sumoylation of SOX2. Although
the role(s) of SOX2 sumoylation remain to be fully characterized, sumoylation of mouse Sox2
has been reported to reduce the ability of Sox2 to increase the transcription of Fgf4 and Nanog
[70]. In the future, it will be important to determine whether this reduction in transcriptional
activity is restricted to a small number of genes or is true for most Sox2-regulated genes.
The kinases that phosphorylate threonine residues of mouse Sox2 T118 and humanT118
have been identified. These threonine residues are both located within a consensus nuclear
localization sequence and the HMG domain of SOX2, which is responsible for DNA binding.
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Phosphorylation of human SOX2 onT118 is mediated by the atypical PKCι [65]. Phosphorylation
of this threonine is associated with an increase in the transcriptional activity of SOX2, which was
shown using SOX2 mutants. The transcriptional activity observed with wild-type SOX2, was not
observed with the SOX2 mutant (T118A), but exhibited by the SOX2 phospho-mimetic mutant
(SOX2-T118D). Interestingly, human SOX2-T118A does not appear to alter SOX2 stability. In
stark contrast, the mouse mutant Sox2-T118A reduces Sox2 stability. Mouse Sox2 can be
phosphorylated on T118 by AKT in mouse ESC [71]. Phosphorylation of this serine not only
increases the transcriptional activity of Sox2, it also increases its stability. Remarkably,
phosphorylation of T118 blocks the monomethylation of Sox2 on the adjacent K119 by the
methyltransferase set7 [72]. Methylation of K119 induces the ubiquitination of Sox2 by the E3
ligase WWP2 and the degradation of Sox2 [72]. Thus, the antagonistic phosphorylationmethylation switch mediated by T118-K119 alters the transcription activity and stability of Sox2,
respectively. Importantly, we are not aware of any studies reporting that AKT inhibitors reduce
the stability of SOX2 in tumor cells. This warrants attention given the use of AKT inhibitors in
many cancer clinical trials. As discussed earlier, AKT has been implicated in a negative feedback
top that influences the transcription of the Sox2 gene in ESC [18].
Sox2 can also be ubiquitinated on K123, which is located just beyond the C-terminal
portion of the DNA binding domain of Sox2 (the HMG domain). The ubiquitin-conjugating
enzyme E2S (Ube2s) mediates K11-linked polyubiquitination of Sox2 at this site [73]. When
ubiquitinated on K123, Sox2 is targeted for proteasome-mediated degradation. The comparable
lysine of human SOX2 is K121. Although SOX2-T118A does not appear to be less stable than
wild-type SOX2 in lung squamous cell carcinoma cells, it is possible in some tumor cells that
phosphorylation of T118 (human SOX2) may block ubiquitination of SOX2 at K121, as was
discussed above for T118 (mouse Sox2), and its influence on the methylation of K119 and the
subsequent degradation of Sox2.
In addition to Sox2 methylation and O-GlcNAcylation discussed above, SOX2 can also
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be methylated and O-GlcNAcylated on other amino acids. Sox2 T258 has been shown to be
modified by O-GlcNAcylation in mouse ESC. Thus far, the function of T258 O-GlcNAcylation
has only been studied in the context of double and triple mutants (T258A/S259A and
S248A/T258A/S259A). The double mutant reduced the ability of Sox2 to reprogram somatic
cells to iPS cells; whereas the triple mutant did not [68]. Additionally, Sox2 can be methylated on
R113 by the arginine methyltransferase CARM1, which increases SOX2 self-association and
increases the transcriptional activity of Sox2 [74]. However, further study will be needed to
determine whether the increase in Sox2 transcriptional activity is linked to its self-association.
Furthermore, it is possible that methylation of Sox2 R113 increases its association with other Sox
family members [74, 75]. Additionally, R113, which is also located within HMG domain of
Sox2, is located within a second Sox2 nuclear localization sequences (NLS2). Interestingly, the
Sox2-R113K mutant, which cannot be methylated, did not alter the subcellular location or the
stability of Sox2 [74].
Finally, Sox2 has been shown to be acetylated within its DNA binding domain on K75 in
vivo. Although the acetyltransferase that acetylates Sox2 in vivo has not been determined
definitively, p300/CBP is a likely candidate, especially since Sox2 can be acetylated by
p300/CBP on K75 in vitro[76]. Moreover, Sox2 has been shown to recruit p300 to the Fgf4
enhancer in ESC [77]. Blocking acetylation of Sox2 in ESC, as shown with the Sox2-K75A
mutant, led to retention of Sox2 in the nucleus and maintenance of its transcriptional activity;
whereas, the acetyl-mimic Sox2-K75Q mutant, associates with the nuclear export machinery,
specifically Crm1 [76]. Other studies indicate that Sox2 can be deacetylated by Sirt1, a member
of the sirtuin family of NAD-dependent protein deacetylases [78, 79]. Acetylation of Sox2 not
only affects its function in ESC, a low level of Sox2 acetylation enhances reprogramming of
somatic cells to iPS cells [79].
It is clear from the discussion in this section that post-translational modifications of
SOX2 dramatically alter its function, and undoubtedly play key roles in helping to adjust the
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levels of SOX2 needed to support cellular function. However, many questions remain to be
addressed. In addition to the enzymes responsible for creating the variety of SOX2 posttranslation modifications, enzymes that remove some of these modifications of SOX2 have not
been identified. Besides phosphatases, likely candidates include deubiquitinating enzymes
(DUBs). Interestingly, proteomic analysis of the SOX2-interactome indicates that SOX2
associates with several DUBs that exert important roles in tumor cells, including USP9X, USP7,
USP15, USP24, and USP34 [80-82]. In the future, defining the roles of each of the SOX2
modifications and the enzymes involved in tumor cells may provide valuable insights into
possible strategies for targeting SOX2 in a large number of cancers. An equally important
question that warrants careful attention is the extent to which any given SOX2 molecule is
simultaneously modified by more than one post-translational modification. By analogy to the
histone code, a “SOX2 code” of post-translational modifications is likely to play a key role in
orchestrating the formation of the multitude of SOX2-protein complexes (SOX2-interactome)
needed to properly control the level, transcriptional activity, subcellular localization, and stability
of SOX2.

1.3

SOX2 is Essential during Mammalian Embryogenesis
The essential role of Sox2 during mammalian embryogenesis was first shown by

knockout of both Sox2 alleles and it was determined that Sox2 null embryos reach the blastocyst
stage in which the inner cluster of cells in the developing embryo has formed an inner cell mass,
but these developing embryos do not survive after implantation [2]. However, the stage at which
Sox2 knockout embryos arrest may be influenced by Sox2 from maternal sources, which is
present in mature oocytes as well as at fertilization [2]. The role of maternal Sox2 during
embryogenesis was the subject of two studies that reached different conclusions. Keramari et al.
used Sox2 siRNA to knockdown both maternal and zygotic Sox2 [83]. This study led to the
conclusion that Sox2 is needed for the embryo to transition into the blastocyst stage. However, a
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subsequent study reached a different conclusion. Initially, Wicklow et al used Zp3-Cre to delete
maternal Sox2 in the early embryo [84]. Importantly, mating Sox2fl/fl/Zp3Cre females to wildtype males led to healthy offspring at numbers expected for normal litters. Thus, maternal Sox2 is
not required for normal development. Furthermore, Wicklow et al determined that combined
knockout of both maternal and zygotic Sox2 did not block formation of the blastocyst [84]. Thus,
despite the study by Keramari et al, Sox2 does not appear to be needed for the specification of the
inner cell mass and surrounding trophectoderm in the early blastocyst [83]. It is also unclear why
the use of Sox2 siRNA generated different results. The two most likely explanations, off-target
effects of Sox2 siRNAs and the general toxicity of siRNA, were experimentally addressed by
Keramari et al [83]. Thus, caution must be exercised when interpreting results where siRNA is
used to study mammalian embryogenesis. Overall, studies of Sox2 null embryos established that
Sox2 is essential during embryogenesis and argues that the first lineage decision during
embryogenesis, specifically the formation of blastocysts, does not require Sox2.
However, additional studies have shown that Sox2 influences the second cell lineage
decision, in particular primitive (extraembryonic) endoderm gene expression, in an Fgf4dependent manner. The second major cell lineage decision made during embryogenesis is the
generation of the epiblast and primitive (extraembryonic) endoderm from the inner cell mass. As
normal development proceeds to the blastocyst stage, Sox2 has already become restricted to the
inner group of cells. At the blastocyst stage, the inner cell mass exhibits a restricted “salt and
pepper” distribution where Sox2, is expressed in some cells and not in others [85]. Once the
embryo reaches the epiblast stage, Sox2, Nanog, and Fgf4 are restricted to the epiblast. Wicklow
et al reported that Sox2 null blastocysts express ~70% less Fgf4 than their wild-type counterparts
[84]. This led them to test whether treatment of cultured Sox2 null embryos with Fgf4 would
promote the expression of primitive (extraembryonic) endoderm markers. Treatment of wild-type
embryos with Fgf4 increases Sox17 expression, but the increase in Sox17 expression exhibited by
Sox2 null embryos treated with Fgf4 was substantially higher. In this connection, it is important
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to note that although E3.75 Sox2 null embryos exhibit low Sox17 expression, E4.25 Sox2 null
embryos express Sox17 and several other PrE-expressed genes (Gata6, Gata4, and Pdgfra). In
fact, Sox2 null embryos at E4.25 express Sox17 and Gata6 at levels similar to wild-type embryos.
Thus, Sox2 influences primitive (extraembryonic) endoderm differentiation. However, it is
unclear whether Sox2 accelerates the onset of primitive (extraembryonic) endoderm gene
expression or, as suggested by Wicklow et al, Sox2 is needed for initial expression of these genes,
but not for their later expression [84]. Importantly, these investigators also reported that Sox2 is
needed to maintain the epiblast starting at E4.25, again confirming the important role of multiple
stages of mammalian embryogenesis.

1.4

Sox2 levels are optimized to support both self-renewal and pluripotency of ESC
In addition to the critical functions of Sox2 in the developing embryo, numerous reports

have examined the role of Sox2 in the self-renewal and pluripotency of ESC. Studies in this
laboratory, which focused on the transcriptional activity of Sox2, led to the prediction that
elevating Sox2 in ESC would induce differentiation [86, 87]. Initially, we determined that
increasing the levels of Sox2 in F9 ECC inhibits the activity of the Fgf4 promoter [85].
Subsequently, we determined that elevating Sox2 decreased the activities of Oct4, Nanog, UTF1,
and Sox2 promoter/reporter gene constructs that were transiently transfected into F9 ECC, as well
as in ESC [87]. Interestingly, although elevating Nanog or Oct4 could inhibit their own
promoters, only when Sox2 levels were elevated were the activities of all five promoters
inhibited. Importantly, small increases in the levels of Sox2 not only decreased the activities of
the five promoters, it also reduced the transcripts for Sox2, Oct4, Nanog, Utf1, and Fgf4 [87].
Currently, relatively little is known about the mechanisms by which elevated levels of
Sox2 inhibit Sox2, Oct4, Nanog, Utf1, and Fgf4 promoters. However, using promoter/enhancerreporter gene constructs, elevated Sox2 has been shown to act on the enhancers that are bound by
Sox2 and Oct4 in each of these genes [87]. Additionally, we has shown that elevating Sox2 in i-
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OSKM-ESC inhibits the transcription of the endogenous Sox2 gene by activating a negative
feedback loop that leads to the phosphorylation and the translocation of FoxO1 (an activator of
Sox2 transcription) into the cytoplasm [18]. More recent studies also point to Sox2 autoregulation
of Sox2. Allele-specific analysis of Sox2 transcripts in ESC indicates that inactivation of one
allele leads to increased transcription of the remaining allele [8]. Thus, ESC are able to carefully
regulate Sox2 transcription. It is proposed that this also occurs during embryogenesis.
The recognition that small increases in Sox2 reduce the expression of several genes
known to be essential for the self-renewal of ESC led us to the hypothesis that small increases in
Sox2 would trigger their differentiation. To test this hypothesis, we engineered ESC for inducible
overexpression of Sox2 [17]. When Sox2 levels were elevated ~2-fold, the cells underwent
pronounced morphological changes indicative of differentiation. Gene expression analysis
demonstrated that pluripotency-associated genes (e.g. Nanog) were downregulated; whereas
genes associated with neuroectoderm, mesoderm, and trophectoderm, but not endoderm, were
upregulated. Interestingly, massive cell death occurs when Sox2 levels were elevated ~5-fold in
ESC. Thus, it is imperative that Sox2 levels are limited in ESC, even when differentiation is
initiated.
Reducing Sox2 levels in ESC has also been reported to induce differentiation. Chew et al
demonstrated that stable transfection of ESC with a vector, which constitutively expresses Sox2
siRNA, reduced Sox2 levels (~50%) and led to a loss of self-renewal [3]. Unlike Oct4 in ESC,
~50% reduction in Sox2 appears to be sufficient to cause the ESC to differentiate. The
differentiated cells exhibited a marked change in morphology and expressed trophectocerm
markers Cdx2 and Hand1. Together, the knockdown and overexpression studies argue that Sox2
levels are optimized in ESC: both small decreases and small increases disrupt their self-renewal
and induce differentiation.
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1.5

SOX2-Protein Interactomes Identify Critical Understudied Proteins, like Musashi2, in

Multiple Cell Types
During the past 10 years, considerable effort has been devoted to understanding the
mechanisms by which essential transcription factors mediate their effects. More recently,
significant strides have been made toward mapping protein-protein interaction landscapes of
essential transcription factors in a number of cellular systems. For example, extensive progress
has been made in determining the proteome of transcription factors, in particular Sox2, Oct4, and
Nanog, necessary for maintaining the self-renewal and pluripotency of ESC [82, 88-93]. The
integration of interactomes for Sox2, Oct4, and Nanog, argues that these pluripotency associated
transcription factors are part of a highly integrated protein-protein interaction landscape, which
includes many other transcription factors, chromatin remodeling machinery, DNA repair
machinery, and RNA binding proteins [82, 93-95]. Previous studies in our laboratory identified
proteins which interact with SOX2 in multiple cell types, including ESC, ESC undergoing
differentiation, DAOY, and U87 brain tumor cells. We hypothesized that proteins that interact
with SOX2 in multiple cell types are likely to be necessary for the continued growth and function
of these cells.
These unbiased proteomic screens have proven to be a powerful approach for identifying
under-studied proteins, such as Banf1 and Musashi2 (MSI2), that significantly influence the fate
of ESC [93-97]. Msi2 is part of a family of RNA-binding proteins that includes Musashi1 (Msi1).
Msi1 and Msi2 each contain two RNA recognition motifs, and both Msi1 and Msi2 can be
expressed as more than one isoform due to alternative splicing [98]. Although the roles of
Musashi proteins are far from clear, Msi1 has been shown to block the translation of Numb by
binding to the 3’ UTR of Numb mRNA [99]. Interestingly, knockdown of Msi2 in two leukemic
cell lines led to an increase in Numb at the protein level, but it remains to be determined whether
this is a direct effect of Msi2 [100].
Musashi proteins appear to play important roles during development. Msi1 and Msi2
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have been shown to contribute to the development of the nervous system, where they appear to
work cooperatively to promote the maintenance of neural stem cells [101]. More recently, Msi2
has been shown to influence the behavior of hematopoietic stem cells (HSC) and their
progenitors. Overexpression of Msi2 in HSC in a transgenic mouse model increased the
population of HSC progenitors and decreased the population of their downstream derivatives
[100]. In contrast, knockdown of Msi2 by shRNA in lymphomyeloid progenitors led to an
increase in the proportion of more mature differentiated myeloid cells [102]. The importance of
Msi2 during hematopoiesis is also evident from the finding that Msi2 null mice exhibit significant
defects in HSC. Interestingly, Msi2 null mice are smaller than their wild-type counterparts, they
are produced at lower than expected frequencies, and Msi2 null mice are infertile when mated
together [103, 104]. The reasons for each of these defects remain to be determined.
In addition to influencing development, Msi2 has also been linked to tumorigenesis.
Importantly, recent studies have shown Msi2 is overexpressed in chronic myelogenous leukemia
(CML) and acute myeloid leukemia (AML) [100, 103]. In CML, Msi2 is elevated ~10-fold
during the more aggressive blast crisis phase than in the chronic phase, and elevated Msi2
expression in CML has been linked to relapse and poorer prognosis [103]. Consistent with these
findings, knockdown of Msi2 by shRNA in blast crisis CML cells led to a more differentiated cell
population and diminished proliferation of the diseased cells [103]. Additionally, knockdown of
Msi2 in several leukemic cell lines reduced their proliferation and led to increased differentiation
and apoptosis [100]. While these studies have advanced our understanding of roles of Msi2 in
multiple cell types, much remains to known, particularly in ESC and brain tumor cells.

1.6

SOX2 Expression in Cancer: Amplification, Prognosis, and Survival
SOX2 expression has been reported at both the RNA and protein levels in over 20

cancers. Data available from The Cancer Genome Atlas indicates that SOX2 mRNA is elevated
in many cancers, relative to normal tissue. For example, SOX2 is reported to be elevated in >85%
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of glioblastoma multiforme samples compared to normal controls [105]. Interestingly,
hypomethylation of the SOX2 promoter was detected in over 250 glioblastoma specimens
compared to normal controls [105]. In tumors such as glioblastoma, ovarian, esophageal, lung,
oral, prostate, and sinonasal carcinoma, SOX2 has been shown to be amplified in some subsets of
patient tumors [105-116]. One study found SOX2 to be amplified in 26% of serous ovarian
cancers [107], and the SOX2 locus (3q26.33) was amplified in ~8% of glioblastoma cases [105],
suggesting an increase in copy number is only a piece of a much larger puzzle regarding SOX2
expression in cancer.
For most cancers, SOX2 expression has also been documented at the protein level by
immunohistochemistry [42, 105, 106, 108, 111, 113, 114, 117-127]. For example, in a study of
breast cancer patients, SOX2 was strongly detected by immunohistochemistry in the nucleus of
breast carcinoma cells compared to weak or no SOX2 staining in normal mammary epithelial
tissue [117, 128]. Although SOX2 expression has been reported in many cancers [105-126, 128131], the percent of SOX2-positive cells within SOX2-positive tumors is not consistently
reported. However, in the case of ovarian cancer, both the percent of SOX2-positive tumors and
the percent of SOX2-positive cells within these tumors have been reported [123]. Interestingly,
the percent of SOX2-positive cells differs between different ovarian tumor subtypes [123].
In several cancers, the levels of SOX2 expression at different stages of the cancer has
been examined [122]. In pancreatic ductal adenocarcinomas (PDAC), SOX2 is rarely expressed
in pre-malignant pancreatic intraepithelial neoplasia (PanIN), but its expression has been reported
to increase to ~60% in poorly differentiated and neurally invasive components [125]. Similarly,
studies in glioblastoma, esophageal, breast, and prostate cancers have reported that SOX2 levels
increase with increasing tumor grade [106, 126, 128, 132, 133], and the percentage of SOX2positive cells correlates with Gleason score [134]. In the case of ovarian epithelial carcinoma,
SOX2 expression was reported to increase from ~55% of normal ovarian epithelia to over 90% of
serous and mucinous cystadenocarcinomas [123]. Interestingly, in the case of gastric cancer,
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reports regarding the levels of SOX2 expression during tumor progression are conflicting. In one
study, SOX2 mRNA was reported to be significantly elevated compared to adjacent benign tissues
[129]. In contrast, other studies reported lower SOX2 expression in gastric cancer and its
metastatic lesions compared to matched, normal gastric mucosa [40, 42, 127, 135]. However,
SOX2 expression also appears to vary with different mucosal subgroups in gastric cancer [127,
136]. Thus, for several cancers, there is a need to more carefully determine how SOX2 levels
change during tumor progression. Undoubtedly, recognizing how SOX2 expression is altered
between normal and tumorous tissues is important for understanding molecular changes
necessary for tumor development and progression.
In addition to determining how SOX2 levels change during tumor progression, it is
essential to determine whether SOX2 levels influence clinical prognosis for cancer patients.
Studies reported thus far indicate that high SOX2 levels correlate with poor prognosis for patients
with many different cancers, including breast (triple negative), colorectal, esophageal, ovarian,
and lung tumors, as well as nasopharyngeal and sinonasal carcinoma (Table 1.2) [124, 133, 137141]. Furthermore, a higher incidence of recurrence was significantly correlated with SOX2
amplification in sinonasal carcinomas [116], and rectal cancer patients with elevated SOX2
displayed significantly lower disease-free survival following chemoradiotherapy [138].
Additional studies in esophageal, hepatocellular, oral/tongue, and some lung cancers, and have
also found a correlation between elevated SOX2 and decreased survival [124, 133, 141-145]. In
addition to survival and recurrence, in the majority of cancers examined thus far, high SOX2
expression has been linked to the infiltrative and metastatic capacity of tumor cells [41, 42, 143,
146-148]. For example, in the case of colorectal cancer, SOX2-expressing tumors have been
shown to correlate with increased distant and lymphatic metastases [146]. Similarly, in
esophageal squamous cell carcinomas, tumors in which more than 50% of the cells express SOX2
were significantly correlated with increased lymphatic and vascular invasion, poor differentiation,
and incomplete surgical resection [148]. However, high SOX2 levels may not be uniformly
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indicative of poor patient prognosis. For at least four cancers, including gastric cancer and
squamous cell lung cancer, low SOX2 expression has been reported to correlate with poor
prognosis (Table 1.2) [41, 42, 113, 149]. Moreover, for gastric cancer elevated SOX2 levels are
linked to reduced lymph node and distant metastases. The reasons for the contrasting results for
SOX2 levels in different cancers remain to be determined.
Disappointingly, for some cancers, in particular head and neck squamous cell carcinomas
and in ovarian cancer, there are conflicting reports regarding the levels of SOX2 expression and
patient survival [107, 142, 145, 150]. In the case of head and neck squamous cell carcinomas,
initial studies by Lee et al showed that SOX2 expression is correlated with poor prognosis and a
nearly 5-fold higher risk of recurrence [142], but subsequent studies by Bayo et al determined that
SOX2high tumors had a median progression-free survival of 51 months compared to SOX2low
tumors (16 months) and that SOX2high tumors had a >110 month improved overall survival
compared to SOX2low tumors [150]. Questions also exist in the case of ovarian cancer. Belotte et
al reported that tumors with SOX2 amplification had statistically significant improved survival
[107]; however, an earlier study from Wang et al reported that high SOX2 levels in both primary
and metastatic tumor components statistically correlated with significantly worse survival [145].
It is evident from the discussion in this section that there is a clear need for further investigation
into the clinical implications of SOX2 expression, particularly in how SOX2 levels influence
tumor progression and patient survival.

1.7

SOX2 and Tumor-Initiating Cells/Cancer Stem Cells
SOX2 is not only expressed in many types of cancer, it has also been implicated in the

tumor-initiating populations (proposed cancer stem cell population) of many of these tumors
(Table 1.3). Many studies have used putative cancer stem cell markers, such as ALDH1, CD44,
ABCG2, and side population via Hoechst efflux assay, to isolate and enrich for cells capable of
forming tumors [tumor-initiating cells (TIC), sometimes considered cancer stem cells]
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[112, 130, 151-155]. For example, in the case of an ovarian cancer cell line, the side population
exhibited elevated levels of SOX2 mRNA and a higher percentage of TIC when assayed using a
limiting cell dilution tumor assay, the gold standard for assessing the frequency of TIC within a
tumor [154]. However, for most cancers, the link between SOX2 and their TIC has not been
firmly established. For several tumor types, knockdown of SOX2 and/or ectopic expression of
SOX2 have been used to implicate SOX2 in the biology of the TIC [137, 156-160]. For example,
Lee et al and Santini et al determined that stable knockdown of SOX2 in limiting cell dilution
tumor assays dramatically reduced tumor initiation/formation in both head and neck squamous
cell carcinomas, and melanomas, respectively [142, 161]. Conversely, others [162, 163]
generated lung and ovarian tumor cells that stably overexpress SOX2 and reported an elevated
number of TIC when these cells were tested in limiting cell dilution tumor assays. However, as
discussed below, there are concerns over the use of tumor cells engineered to stably overexpress
SOX2.
Arguably the most conclusive studies have linked SOX2 to TIC by isolating the SOX2positive cell population rather than experimentally altering the levels of SOX2 within cells. This
is important, because SOX2 is expressed heterogeneously throughout the cells of many tumors
[137, 150, 164]. Moreover, for some tumors, only a percentage of the cells express SOX2. This is
particularly evident for SOX2-positive tumor cell lines [137, 164, 165]. Thus far, the SOX2positive cells isolated from heterogeneous populations were engineered to either express GFP that
was knocked into the endogenous SOX2 gene (GFP-SOX2 fusion protein) [164, 165] or GFP
driven by a transgene under the control of the SOX2 promoter and enhancer [166]. In these three
studies, SOX2-positive cells exhibited a higher frequency of TIC compared to the SOX2-negative
cells of the same tumor cells population in a limiting cell dilution tumor assay. Furthermore,
studies by Vanner et al not only showed SOX2-positive cells to be important for the tumor
initiation, but also used thymidine-analog retention (label-retaining cells) to show that SOX2positive cells are members of a quiescent, slowly-cycling population within the tumor [164].
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Importantly, a recent study in bladder cancer has shown that the quiescent label-retaining cancer
stem cell population does not respond to cytotoxic therapy and is capable of repopulating the
tumor following drug removal [221]. Such studies not only call attention to a role for SOX2 in the
TIC population, but also that this slowly-cycling, SOX2 positive population may be responsible
for repopulating the tumor after drug treatment is suspended.

1.8

SOX2 and Drug Resistance
Several recent studies have shown that exogenous elevation of SOX2 can promote

resistance to chemotherapeutics currently being used clinically [126, 129, 137, 141, 142, 152,
158, 163, 167-169]. In a report from Bareiss et al, ovarian cancer cell lines that did not express
SOX2 and that were sensitive to carboplatin, cisplatin, and paclitaxel became resistant following
stable, ectopic expression of SOX2 [163]. Furthermore, in a SOX2-expressing ovarian cancer cell
line, SOX2 knockdown using shRNAs provided susceptibility to these drugs, which was reversed
upon re-expression of SOX2 ectopically [163]. Similar results were seen in breast cancer cell
lines, as stable overexpression of SOX2 in MCF-7 cells promoted resistance to tamoxifen, while
stable downregulation of SOX2 using shRNAs enhanced the sensitivity of MCF-7 cells to
tamoxifen [137]. While SOX2 may be acting to protect tumor cells through antiapoptotic
signaling or quiescent-like phenotypes [126, 152, 158, 164], SOX2 may also be promoting drug
resistance through various ATP-binding cassette transporters, including ABCG2, ABCC3, and
ABCC6. In particular, ABCG2 has been shown in various tumors to be upregulated in the side
population TIC [151, 154] and is, in some tumors, considered to be an additional cancer stem cell
marker. Furthermore, studies in lung cancer, as well as head and neck squamous cell carcinoma,
have shown that stable downregulation of SOX2 via shRNAs decreases ABCG2, which
implicates this transporter in SOX2-related drug resistance [142, 159]. Recognizing and focusing
on the role of SOX2 in drug resistance could greatly improve the treatment options for patients
with a multitude of cancers, especially those with highly refractory tumors, as the ability to
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eradicate the TIC population is likely to be the only way to prevent recurrence.

1.9

SOX2 Levels and Tumor Growth
Many studies have used stable overexpression and/or knockdown of SOX2 in tumor cell

lines to better understand the roles of this transcription factor in cancer. Knockdown of SOX2
using either siRNA or shRNA have been used in multiple studies [12, 21, 105, 109, 110, 122,
126, 128, 129, 141, 145, 154, 167, 170, 171]. Importantly, even partial reductions in SOX2 levels
have been reported to significantly decrease cell viability, clonal growth, sphere formation, and
tumorigenicity in multiple cancer types. Clearly, knockdown studies have established that SOX2
plays important roles in these cancers. However, SOX2 overexpression studies have generated
conflicting results. For example, stable overexpression of SOX2 in the gastric tumor cell line N87
was reported to increase growth both in vitro and in vivo [129]. In contrast, stable overexpression
of SOX2 in the gastric cell line MKN28 was reported to decrease growth both in vitro and in
vivo. Currently, the reasons for the conflicting results are unclear. In both studies, SOX2 was
substantially overexpressed in gastric tumor cell lines that endogenously express relatively little
SOX2. Part of the explanation may be due to differences in the cell lines used. However, as
discussed below other factors related to experimental design may also be a contributing factor.
Conflicting reports from SOX2 overexpression studies have also been reported for breast,
prostate and pancreatic cancers. Stable overexpression in MCF7 (breast), DU145 (prostate), and
Patu8988t (pancreatic ductal adenocarcinoma) cells have been reported to increase growth in
vitro [126, 128, 155]. However, overexpression of SOX2 from a doxycycline-inducible transgene
demonstrated that overexpression of SOX2, where one can monitor the early consequences of
elevating SOX2, does not increase cell proliferation. Inducibly elevating SOX2 (~5 to 7-fold) in
glioblastoma (U87, U118), medulloblastoma (DAOY), breast carcinoma (MCF7), and prostate
carcinoma (DU145) cell lines led to growth inhibition in each case [172]. Thus, the immediate
effect of elevating SOX2 in these tumor cell lines is growth inhibition. Clearly, it is important to
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reexamine the effects of SOX2 in other cancers using inducible overexpression of SOX2, in
particular where stable overexpression has been reported to increase tumor cell growth.

1.10

Background on Brain Tumors and PDAC
While SOX2 has been shown to be important in over two dozen tumors, the studies

described in this dissertation have focused on brain tumors and PDAC. Brain tumors, specifically
glioblastomas (GBM) and medulloblastomas (MB) are highly debilitating diseases that are very
difficult to treat. Despite improved therapeutic regimes, patients diagnosed with GBM, the most
common primary adult brain tumor, have a median survival of 10-14 months [173]. Treatment of
patients with MB, the most common pediatric brain cancer, poses an additional problem. Current
therapies for MB cause dramatic impairment of cognitive function and predispose patients to
future treatment-associated neoplasms [174]. Hence, there is a pressing need to identify novel
proteins and signaling pathways that can serve as new targets for improved treatment of GBM
and MB. As briefly outlined above, elevated levels of the transcription factor SOX2, which plays
critical roles in the development of the nervous system, have been shown to correlate with poor
clinical outcome for brain tumor patients [175]. The critical role of SOX2 in brain tumors is
supported by the finding that knockdown of SOX2 by RNA interference reduces the in vitro and
in vivo growth of GBM cells [170]. Moreover, SOX2 is expressed in MB cells [175] and,
recently, it has been determined that the knockdown of SOX2 in DAOY MB cells reduces their
proliferation (Cox and Rizzino, unpublished results).
Pancreatic ductal adenocarcinoma (PDAC) also expresses SOX2 and it is one of the most
lethal malignancies. For several decades, the 5-year survival of patients with PDAC has remained
at or below 7% with a median survival of less than one year for patients with locally advanced or
metastatic disease [176]. In the United States, PDAC is the fourth most common cause of cancer
deaths (~40,000/year), and it is predicted to become the second leading cause of cancer deaths in
the United States by 2030 [177]. The high mortality of PDAC patients is due in large measure to
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late diagnosis of the disease when tumor resection is not feasible and resistance of PDAC to
chemotherapy designed to target aberrantly regulated signaling networks. Consequently, there is a
desperate need to identify new therapeutic targets that influence drug-resistance. Thus far, a wide
range of genes and signaling pathways have been shown to be aberrantly activated in PDAC. The
most common mutation is in the coding region of the KRAS gene, which generates constitutively
activated KRAS in >90% of all PDAC [178]. These tumors are highly dependent on upregulated
AKT and RAF/MEK/ERK signaling, which are downstream of KRAS [179-182]. This led to a
large number of PDAC clinical trials testing AKT inhibitors (AKTi), e.g. MK-2206, and at least
five MEK inhibitors (MEKi), e.g. trametinib [183]. Disappointingly, these drugs have not
produced significant responses in PDAC clinical trials, which has led to the general belief that
PDAC is largely resistant to AKTi and MEKi.
As outlined earlier, SOX2 expression increases significantly during tumor progression
rising from ~20% in pre-malignant PanIN3 lesions to nearly 60% of poorly differentiated PDAC
[125]. Subsequent studies reported that SOX2 is expressed in many different human PDAC cell
lines, with high expression in some PDAC cell lines, but little or no expression in others [155].
Importantly, this study demonstrated that SOX2 expression is closely associated with putative
cancer stem cell markers previously reported to be expressed by PDAC tumor-initiating cells
[155]. This study also demonstrated that knocking down SOX2 in PDAC cell lines reduced their
growth in vitro; whereas, stable expression of SOX2 in a PDAC cell line, which does not
endogenously express detectable levels of SOX2, increased their anchorage-independent growth
[155]. Although this study provided support in vitro for a critical role of SOX2 in the stemness of
PDAC, the effects of SOX2 on the tumorigenicity of PDAC tumor cells were not examined.
Thus, our understanding of SOX2 in PDAC is incomplete, and many important questions remain
unanswered.
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1.11

Dissertation Objectives
The studies presented in this dissertation extend our knowledge of SOX2 and its function

as a master regulator in multiple cell types, and further elaborate on the finding that proteins like
Msi2, which associate with SOX2 in multiple cell types, are also required for continued cell
growth and function.
In this dissertation, two major bodies of work are presented. The first major objective
examined the role of the SOX2-associated protein Msi2 in both ESC and brain tumor cells. As
described in Chapter 3, the results of these studies demonstrate that ESC require Msi2 to maintain
self-renewal and pluripotency. This work regarding Msi2 in ESC was carried forward into studies
of MSI2 in brain tumors, as MSI2 was also identified as a SOX2-associated protein in DAOY
MB cells and GBM cells. Work outlined in Chapter 3 of this dissertation demonstrates that MSI2
is required to support the growth and survival of DAOY cells and two GBM tumor cell lines, U87
and U118.
The second major objective of this dissertation focused on SOX2 and its roles in PDAC.
As described earlier, one study reported that elevation of SOX2 promoted PDAC cell growth;
however previous studies in our laboratory found that inducible elevation of SOX2 in multiple
other cancer cell lines in fact reduces tumor cell growth. To resolve this issue, multiple PDAC
cell lines were engineered for either inducible overexpression of SOX2 or inducible knockdown
of SOX2. Initially, these inducible PDAC cell lines were used to examine the growth in vitro and
tumorigenicity following changes in SOX2 levels. Through these studies, we determined that
SOX2 functions as a biphasic molecular rheostat in PDAC, as described in Chapter 4.
Furthermore, we determined that the sensitivity of PDAC cells to small molecule inhibitors
currently being tested in clinical trials can be altered by changes in SOX2 levels. Specifically,
Chapter 5 details how inducible elevation of SOX2 protects PDAC cells from the growth
inhibitory effects of MEK and AKT inhibitors; conversely, growth inhibition due to these
inhibitors is enhanced by the inducible knockdown of SOX2.
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Altogether, the work presented in this dissertation strengthens our knowledge of SOX2
and SOX2-associated proteins in multiple cell types, and provides useful platforms for the
continued study these highly deadly malignancies.
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CHAPTER 2:

Materials and Methods
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2.1

Cell Culture Conditions
D3 mouse ESC (obtained from T. Doetschman, 1985) and their genetically modified

derivatives (see below) were cultured on tissue culture plastic pretreated with 0.1% gelatin
(G2500, Sigma-Aldrich, St. Louis, MO), in Dulbecco’s Modified Eagle’s Medium (DMEM,
12100046, Invitrogen, Carlsbad, CA) supplemented with 15% fetal bovine serum (FBS,
SH30910.03, Hyclone, Logan, UT), 5 ng/mL leukemia inhibitory factor (LIF, ESG1107,
Millipore, Billerica, MA) and 100 µM β-mercaptoethanol (M7522, Sigma-Aldrich), as described
previously [17]. DAOY (HTB-186, ATCC, Manassas, VA), U87 (HTB-14, ATCC), U118 (HTB15, ATCC), HEK293T (CRL-11268, ATCC), T3M4 (obtained from T. Hollingsworth, UNMC),
BxPC3 (obtained from T. Hollingsworth, UNMC), HPAF-II (obtained from T. Hollingsworth,
UNMC), L3.6 (obtained from D. Billadeau, Mayo Clinic, Rochester, MN) cells and their
genetically modified derivatives (see below) were cultured in DMEM supplemented with 10%
FBS, as described previously [81, 184]. The identity of each of the PDAC cell lines was verified
by genetic analysis, which was performed by the Molecular Diagnostics Laboratory at UNMC.
To differentiate ESC, the cells were treated with 5 µM retinoic acid (RA, 207341000, Acros
Organics, Morris Plains NJ) for 4 days. Doxycycline (Dox; Sigma-Aldrich) was suspended in
phosphate buffered saline at the indicated concentrations. In all engineered lines, Flag-tagged
SOX2 or SOX2 shRNA was induced by supplementing the culture medium with Dox for the
times and at the concentrations indicated. Kinase inhibitors were obtained from companies listed
in Table 2.1. The EC50 for each drug used for each cell line was determined by measurements of
cell growth over a 4 day period (Table 2.1). Photomicrographs taken of cultured cells were
obtained with a Canon Rebel XTi camera at 10X and/or 25X, where indicated.
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2.2

Lentiviral Vector Engineering
2.2.1

pLVX-PGK-TetOn-Advanced

The CMV promoter responsible for driving the expression of the neomycin resistance
gene in pLVX-Tet-On-Advanced (Clontech, Mountain View, CA, #632162) was replaced with a
PGK promoter. For this purpose, the PGK promoter from pLVX-Tight-Puro (Clontech, #632162)
was amplified by PCR, with primers that introduce ClaI and BamH1 restriction sites, upstream
and downstream of the promoter, respectively. The sequence of the upstream primer for
amplifying the PGK promoter was:
CAGTTTATCGATTACCGGGTAGGGGAGGCGCTTTTCCCAAGGCAGTCTGG (ClaI site in
bold font), and the sequence for the downstream primer was:
CATGGTGGATCCCGAAAGGCCCGGAGATGAGGAAGAGGAGAACAGCGCGG (BamHI
site in bold font). The PGK PCR product was digested with ClaI and BamH1 restriction enzymes,
and the fragment was ligated into pLVX-Tet-On-Advanced, previously treated with ClaI and
BamHI to remove the CMV promoter. The resulting modified plasmid is thenceforth referred to
as pLVX-PGK-TetOn-Advanced.

2.2.2

pLVX-Tight-Puro-Flag-Msi2 isoform 1 and pLVX-Tight-Puro-Flag-Msi2

isoform 2
To produce viruses for inducible expression of Flag-tagged Msi2 isoform 1 and Flagtagged Msi2 isoform 2, the coding sequence for Msi2 isoform1 and the coding sequence for
Msi2-isoform2 were first cloned from RNA isolated from D3 ESC and cDNA synthesized, as
described below. The Msi2 coding sequences were amplified by PCR. For this purpose, primers
were designed to add a BamHI restriction enzyme site, Kozak sequence, and a Flag peptide to the
N-terminus of each Msi2 coding sequence, as well as 3 stop codons and an EcoRI restriction
enzyme site to the C-terminus. The upstream PCR primer used was:
ATCGCGGATCCGCCACCATGGACTACAAGGACGACGATGACAAGATGGAGGCAAAT
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GGGAGCCCA (BamHI restriction enzyme site is shown in bold font, followed by the Kozak
sequence, then the Flag peptide sequence, which is underlined). The downstream primer used
was: TACCGGAATTCTTATTATCAGTGGTATCCATTTGTAAAGGCCGTTGC (EcoRI
restriction enzyme site in bold font and stop codons in italicized font). The Flag-Msi2 products
were digested with BamH1 and EcoRI restriction enzymes, and the fragments were ligated into
pBluescript II KS+ (Stratagene), previously digested with BamH1 and EcoRI in the multiple
cloning site. Due to the design of the primers, both Msi2 isoforms 1 and 2 were amplified via
PCR, and ligated into pBluescript II KS+. Sequencing of this library was performed by UNMC
High-Throughput DNA Sequencing Core to identify Flag-Msi2 isoform 1 or Flag-Msi2 isoform 2
clones. Once identified, Flag-Msi2 isoform 1 or Flag-Msi2 isoform 2 fragments were isolated
from the pBluescript II KS+ plasmids by digestion with BamH1 and EcoRI, and ligated into
pLVX-Tight-Puro previously digested with the same enzymes. These plasmids were then called
pLVX-Tight-Puro-Flag-Msi2 isoform 1 and pLVX-Tight-Puro-Flag-Msi2 isoform 2.

2.3

Transient Transfection
Transient transfection of HEK293T (293T) cells was performed using the calcium

phosphate precipitation method, as described previously [185]. Specifically, plasmid DNA for
transfection and 150 µl of 2.5M CaCl2 are added to 1.35 mL H2O. This mixture is then added to
1.5 mL of HEPES buffered saline, pH 7.1 (HBS, 1.64% (w/v) NaCl, 1.19% (w/v) HEPES
(H4034, Sigma-Aldrich), dropwise with bubbling to mix. The 3 mL DNA precipitate solution is
then added dropwise over the surface of a 150 mm dish of cells plated 24 hours earlier.

2.4

Lentiviral Production and Transduction
To produce lentivirus, HEK293T cells were transiently transfected (as detailed above)

with 45 µg transfer vector (pLVX-PGK-TetOn-Advanced, pLVX-Tight-Puro-Luc (632162,
Clontech), pLVX-Tight-Puro-Flag-Msi2 isoform 1, or pLVX-Tight-Puro-Flag-Msi2 isoform 2,
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RMM4534-NM_054043, RMM4534-NM_011443, pLVX-tetO-(fs)SOX2, RHS4696-201902991,
or RHS4696-201899634, as specified below), 30 µg packaging vector psPAX2 (12260, Addgene,
Cambridge, MA), and 15 µg envelope vector pMD2.G (12259, Addgene) using the calcium
phosphate precipitation method described above. Twenty-four hours later, the cells were refed
with 15 mL DMEM, 10% FBS, 10 mM HEPES, and 10 mM sodium butyrate (303410, SigmaAldrich). After 24 hours, the media was collected, filtered (0.45 µm) and stored at 4°C overnight
and transfected cells were refed with 15 mL of same media as day before. The following day, the
second day media was again collected and filtered. The filtered media was combined, and viral
particles were collected by ultra-speed centrifuge with an SW-28 rotor at 26,000 rpm at 4°C for 2
hours. Lentiviruses were resuspended in 550 µL pre-chilled DMEM with 10% FBS and 10 mM
HEPES at 4°C overnight, aliquoted into 50 µL, and stored at −80°C. To infect cells, one ~50 µl
aliquot of lentivirus was diluted in ~7 ml of the appropriate cell medium for a given cell type
supplemented with 10 mM HEPES and 6 μg/ml polybrene (H9268, Sigma-Aldrich).

2.5

Engineering ESC that Inducibly Express Msi2 isoform 1 or isoform 2
Lentiviral particles were produced from pLVX-Tight-Puro-Flag-Msi2 isoform 1, pLVX-

Tight-Puro-Flag-Msi2 isoform 2, or pLVX-Tight-Puro-Luc (632162, Clontech) in 293T cells as
described above. To produce ESC that express either Flag-tagged Msi2 isoform 1 or Flag-tagged
Msi2 isoform 2, D3 ESC were first infected with the lentiviral vector pLVX-PGK-TetOnAdvanced to express the reverse tet transactivator. Virally transduced cells, referred to as D3rtTA ESC, were isolated after treatment with 300 µg/mL G418 sulfate (A1720, Sigma-Aldrich)
for 6 days. To produce i-Msi2.1-D3 ESC and i-Msi2.2-D3 ESC, D3-rtTA ESC were infected with
the virus pLVX-Tight-Puro-Flag-Msi2 isoform 1 or pLVX-Tight-Puro-Flag-Msi2 isoform 2.
Twenty-four hours after infection, D3-rtTA ESC were cultured in the presence of 5 µg/ml
puromycin (P8833, Sigma-Aldrich) for 48 hours to select for infected cells. Flag-tagged Msi2
isoform 1 and Flag-tagged Msi2 isoform 2 were individually expressed from inducible transgenes
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stably integrated into i-Msi2.1-D3 ESC and i-Msi2.2-D3 ESC, respectively. The recombinant
proteins were induced by the addition of 1 μg/ml Dox.

2.6

Knockdown of Msi2 in D3 mouse ESC
Msi2 was knocked down in D3 ESC that had been seeded at a density of 105 cells per

well in a 6-well plate. A previously validated non-specific shRNA (Scrambled) was used as a
negative control in knockdown experiments [186]. One day later, cells were infected with
lentiviruses that express either the scrambled shRNA or shRNAs targeting Msi2 (Msi2 shRNA
#1, #4, or #5). Lentiviral vectors for expression of shRNA sequences that target mouse Msi2 were
obtained from Open Biosystems (RMM4534-NM_054043, Huntsville, AL). Msi2 shRNA
lentiviral constructs #1, #4, and #5 used in this study correspond to TRCN0000071973,
TRCN0000071976, and TRCN0000071977, respectively. Sequences of these shRNAs are
provided in Table 2.2. Production of these shRNA lentiviral particles in HEK293T cells is
described above.

2.7

Knockdown of MSI2 in Glioblastoma and Medulloblastoma Tumor Cells
To knockdown MSI2 in DAOY, U87, and U118 tumor cells, cells were infected with

lentivirus made using vectors containing shRNAs that target MSI2 (RMM4534-NM_011443,
Open Biosystems), as well as the scrambled control shRNA. Sequences for these shRNAs are
provided in Table 2.2. Notably, shRNA #4 and shRNA #5 target both mouse and human forms of
MSI2 with the same targeting sequence. Production of these shRNA lentiviral particles in
HEK293T cells is described above.

2.8

Engineering PDAC cells for SOX2 overexpression and knockdown
PDAC cell lines were engineered for Dox-inducible SOX2 expression as described

previously [172]. T3M4 cells were first transduced with the reverse tet transactivator lentiviral
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vector (pLVX-PGK-TetOn-Advanced) and a G418-resistant clone selected for in medium
containing 300 µg/mL G418 sulfate for 9-12 days. Secondly, these cells were infected with
lentivirus containing the pLVX-tetO-(fs)SOX2 lentiviral vector (Figure 2.1) and were selected for
in medium containing 5 µg/ml puromycin for 48 hours, resulting in i-SOX2-T3M4 cells. The cell
lines i-SOX2-BxPC3 and i-SOX2-HPAF-II were engineered by infection with both viruses
simultaneously prior to selection.
For inducible knockdown of SOX2, T3M4 and L3.6 cell lines were engineered for Doxinducible expression of an shRNA using a TRIPZ lentiviral vector obtained from Open
Biosystems (now GE Dharmacon, Lafayette, CO). This vector, RHS4696-201902991, has a
mature antisense sequence of ACATGCTGATCATGTCCCG, which targets the ORF of both
human and mouse SOX2. In T3M4 cells a second, independent lentiviral vector was used. This
second vector, RHS4696-201899634, has a mature antisense sequence of
TTCTTGTCGGCATCGCGGT. The TRIPZ vector results in puromycin resistance and
constitutive expression of a reverse tet transactivator as well as Dox-inducible expression of the
shRNA and red fluorescent protein (RFP). I-KdSOX2-T3M4 and i-KdSOX2-L3.6 cell lines were
isolated after puromycin selection, as described above. The i-KdSOX2-T3M4 cell population was
further enriched by flow cytometry for cells with higher RFP expression following an 18 hour
induction with 1 µg/mL Dox.

2.9

Colony Forming Assays
ESC were plated at clonal densities and maintained in ES-cell media for up to 6 days, at

which point the number of colonies that exhibited only the morphology of ESC, a mix of ESC
and differentiated cells, or only cells with a differentiated morphology were counted in 10
random 40X fields by an observer unaware of sample designation. For PDAC cloning efficiency
assays, cells were plated at clonal densities (80 cells per cm2) and maintained in serum containing
media (as indicated above). After 8-12 days, the number of colonies (8 or more cells per colony)
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was determined in 15-20 random 40X fields by an observer unaware of sample designation. For
replating efficiency assays, cells were grown at subconfluent densities for 6 days with or without
treatment in normal media (as indicated above), at which point the cells were trypsinized and
replated at clonal densities in normal media. After an additional 7 or 11 days, the number of
colonies that exhibited 8 or more cells per colony was determined in 8-15 random 40X fields by
an observer unaware of sample designation.

2.10

Soft Agar Growth Assays
Soft agar growth assays were performed in serum-free, stem cell medium, as described

previously [81]. The number of spheres that exhibited 8 or more cells per sphere was determined,
and spheres larger than 50 µm in diameter were scored as large.

2.11

Alkaline Phosphatase Staining
ESC were stained for alkaline phosphatase using an AP-staining kit, according to the

manufacturer’s protocol (00-0009, Stemgent, San Diego, CA).

2.12

MTT Assays
MTT assays of triplicate samples were used to assess relative cell growth, as described

previously [187, 188]. MTT assays were used to assess proliferation using mitochondrial
dehydrogenase activity as a measure of cell number, was described previously [187, 188]. Cells
were cultured in 12-well plates and, when appropriate depending on experimental design, cells
were refed 750 µL culture medium + 250 µL MTT reagent (5 mg/mL MTT (M2128, SigmaAldrich) in PBS), and placed in a cell culture incubator for 2 hours. 750 µL of MTT solvent (20%
(w/v) SDS in 1:1, water:DMF (D4551, Sigma-Aldrich), pH adjusted to 4.7 with 2.5% (v/v): 80%
(v/v) acetic acid (A38C-212, Fisher) and 2.5% (v/v) 1N HCl [A144-500]) was added to each well,
and the 12-well plate was returned to the cell culture incubator overnight. The next day, the
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absorbance of each well was read at 570 nm using a spectrophotometer. Each sample was treated
and measured in triplicate. Controls were averaged and set to 1. Error bars represent standard
deviation between the three replicates and p values were determined by student’s t-test (*p<0.05,
**p<0.01, and ***p<0.005).

2.13

Protein Isolation and Micro BCA Quantification
Nuclear and cytoplasmic protein extracts were prepared using NE-PER kits (Thermo-

Scientific, Rockford, IL) according to the manufacturer’s protocol to isolate proteins for western
blot analysis. Whole cell protein extracts were prepared using RIPA extraction buffer [150 mM
NaCl (S9888, Sigma-Aldrich), 50 mM Tris-HCl (pH 7.4, 10812846001, Sigma-Aldrich), 1%
IGEPAL (I8896, Sigma-Aldrich), 0.25% sodium deoxycholate (D6750, Sigma-Aldrich), and 1
mM EDTA (E6758, Sigma-Aldrich)] supplemented with the following protease and phosphatase
inhibitors: Na3VO4 (5 mM, S6508, Sigma-Aldrich), PMSF (1 mM, P7626, Sigma-Aldrich), NaF
(10 mM, S7920, Sigma-Aldrich), EDTA (10 mM, E6758, Sigma-Aldrich), leupeptin (1 µg/mL,
L2884, Sigma-Aldrich), pepstatin A (2 μM, P5318, Sigma-Aldrich), chymostatin (1 µg/mL,
C7268, Sigma-Aldrich), aprotinin (2.5 KIU/mL, A1153, Sigma-Aldrich), soybean trypsin
inhibitor (20 µg/mL, T9003, Sigma-Aldrich), and NaPPi (30 mM, P8135, Sigma-Aldrich).
Protein extract concentrations were quantified using the Micro BCA™ Protein Assay Kit (23235,
Pierce), according to the manufacturer’s guidelines.

2.14

Western Blot Analysis
Western blot analysis was performed as described previously [82, 97]. Primary mouse

antibodies used were: α-Msi2 (ab76148, Abcam, Cambridge, MA, 1:2,000), α-Sox2 (#2683-1,
Epitomics, Burlingame, CA, 1:5,000), and α-Oct 4 (sc8628, Santa Cruz, Santa Cruz, CA, 1:500).
Primary human antibodies used were: α-MSI2 (ab83236, Abcam, Cambridge, MA), α-NUMB
(ab4147, Abcam), α-SOX2 (ab92494, Abcam, Cambridge, MA, 1:1,000), and α-phospho-p44/42
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MAPK antibody (#9106, Cell Signaling Technology, Danvers, MA, 1:1,000). HDAC1 (ab-7028,
Abcam, 1:5,000) and α-GAPDH (G8795, Sigma-Aldrich) were used as loading controls. MSI2,
SOX2, and HDAC1 primary antibodies were detected with an anti-rabbit-IgG-AP secondary
antibody (A3687, Sigma-Aldrich, 1:10,000). Oct4 and Numb primary antibodies were detected
with an anti-goat-IgG-AP secondary antibody (A4187, Sigma-Aldrich, 1:10,000). PhosphoERK1/2 and GAPDH primary antibodies were detected with an anti-mouse-IgG-AP secondary
antibody (A4312, Sigma-Aldrich, 1:10,000).

2.15

RNA Isolation and Expression Analysis
D3 ESC were infected with lentiviruses that express either scrambled shRNA or Msi2

shRNA #1 for 24 hours followed by selection with puromycin for 24 hours. Cells were
subcultured 48 hours after puromycin selection at a low density (4,500 cells per cm2). Cells were
maintained for 4 days in normal ES cell media followed by RNA isolation and cDNA synthesis as
described previously [17]. Expression of ES-related genes and lineage-specific genes in D3 ESC
treated with Msi2 shRNA #1 and scrambled shRNA were analyzed by SYBR Green
(SuperArrayBioscience Corporation, Frederick, MD) quantitative Real-Time polymerase chain
reaction (RT-qPCR) [17, 82]. Similarly, i-Msi2.1-D3 and i-Msi2.2-D3 were treated with or
without 1 μg/ml Dox for 48 hours prior to plating at 4,500 cells/cm2. Cells were then treated with
and without Dox in the presence of 5 μM RA for 48 hours, followed by the removal of LIF for 48
hours to further differentiate the cells prior to the RNA extraction and cDNA synthesis. Primers
for Msi2 isoforms, Msi1, Numb, Sox7, and Tfec are provided in Table 2.3. Primers for ES celland lineage-specific transcripts have been described previously [17, 82, 87]. Gene expression of
MSI2 in DAOY, U87, or U118 cells treated with targeting or scrambled shRNA were analyzed
by SYBR Green RT-qPCR , as described above. Primers used for the PCR step in the analysis of
MSI2 RNA were h-MSI2-F (AAGTATTAGGTCAGCCCCAC) and h-MSI2-R
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(TTCTCAAAAGTGACAAAGCC). Primers for GAPDH control expression have been described
previously [97].

2.16

Microarray Analysis
RNA isolated from D3 ESC infected with lentiviruses that express either scrambled

shRNA or Msi2 shRNA #1, as described above, was used for genome-wide RNA expression
analysis. Sense-strand cDNA was generated from 300 ng total RNA using the Ambion WT
Expression kit for Affymetrix Whole Transcript Expression Arrays (Affymetrix, Santa Clara,
CA). This cDNA was fragmented and labeled using the GeneChip® WT Terminal Labeling and
Hybridization (Affymetrix) followed by hybridization for 16 hours at 45°C to an Affymetrix
GeneChip Mouse Gene 1.0 ST (Affymetrix). Gene chips were washed and stained with the
Affymetrix Fluidics Station 450 (Affymetrix) prior to being scanned by the Affymetrix GeneChip
Scanner 3000 7G (Affymetrix). Data was analyzed with Affymetrix Expression Console software
(Affymetrix) using Robust Multichip Analysis (RMA) for normalization. Data collection and
analysis were performed by the University of Nebraska Medical Center DNA Microarray Core
Facility. Microarray data was sorted for genes that increase or decrease 2-fold or more when Msi2
shRNA #1 was compared to the control scrambled shRNA. Of these genes, the Database for
Annotation, Visualization and Integrated Discovery (DAVID) was used to classify them into
broad-based cellular and molecular functions [189, 190]. All microarray data is available on Gene
Expression Omnibus (Accession No. GSE33882, GEO, http://www.ncbi.nlm.nih.gov/geo/).

2.17

Cell Cycle Analysis
I-SOX2-T3M4 cells were seeded at subconfluent densities in the presence or absence of

Dox (300 ng/ml) and MEKi were added the following day. After 3 days treatment with each
MEKi in the presence or absence of Dox, cells were prepared for cell cycle analysis by the
Telford Method, as described previously [191]. Floating cells were included in the cell cycle
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analysis. Flow analyses were performed by the UNMC Cell Analysis core facility.

2.18

Determination of Tumorigenicity
Female NCr-nu/nu mice (7 weeks of age) were obtained from Charles River

(Wilmington, MA). All animal procedures were approved by the UNMC Institutional Animal
Care and Use Committee. Where indicated, 2.5x105 i-SOX2-T3M4 cells or 2.5x105 i-KdSOX2T3M4 cells were trypsinized, washed, resuspended in 50 µl of sterile PBS and injected
subcutaneously into the flank. Tumor growth was monitored daily. After palpable tumors had
formed, tumor-bearing mice were randomized to size-matched control and experimental (Doxtreated) groups. Dox-treatment for elevation or knockdown of SOX2 was accomplished by
addition of Dox (2 mg/ml) to drinking water that contained 5% sucrose. Untreated mice were
provided with 5% sucrose drinking water as a control. Tumor volumes were calculated based on
measurements with a digital caliper at the times indicated. At the completion of the tumor growth
study, mice were euthanized and tumors excised for weight measurements and
immunohistochemical analysis.

2.19

Immunohistochemical Analysis
Formalin-fixed tumor sections were paraffin-embedded and stained for hematoxylin and

eosin (H&E), SMA, and Ki-67 by the University of Nebraska Medical Center Tissue Sciences
Facility. H&E, SMA, and Ki-67 stained photomicrographs were captured using either an iScan
Coreo Au Scanner with iScan Coreo 3.4.0 software (Ventana Medical Systems, Inc., Tucson,
AZ), or a Nikon Digital Sight DS-Fi1 camera with NIS Elements 4.0. software (Nikon, Inc.,
Melville, NY). Quantification of the stromal component of tumors was assessed by overlaying a
grid on top of photomicrographs of SMA stained tumor tissues using Adobe Photoshop 2015.0.1.
An area of 1 mm2 was divided into 864 squares, which were examined for positive staining,
indicating stroma. Two independent tumors from each treatment condition (e.g. i-SOX2-T3M4
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cells or i-KdSOX2-L3.6 cells, without Dox and with Dox) were assessed, and the percentages of
SMA positive squares were averaged and standard deviation calculated for each condition.
Proliferation in tumors was assessed by staining for Ki-67, and counting the number of positively
stained cells out of at least 500 cells, only in the carcinoma or stromal components of each tumor
growth condition. As with the stromal quantification, two independent tumors from each
treatment condition were scored, and Ki-67 incidence in the stroma or carcinoma was averaged
and standard deviation calculated. The student’s T-test (2-tailed) was used to determine statistical
significance (p < 0.05) using Microsoft Excel for Mac (15.20).

2.20

Immunofluorescence Assays
Immunofluorescence assays used to assess SOX2 expression in PDAC cell lines. Cells

were cultured in 8-well chamber slides (354118, Corning Falcon Fisher) with 300 µL culture
medium per well and placed in a cell culture incubator for 3 days. When appropriate, cells were
washed with 1X PBS prior to fixation with 200 µl 100% methanol (chilled to -20°C) at room
temperature for 5 minutes. Cells were then permeabilized with 0.3% TritonX-100 and blocked in
animal serum (5% in 0.3% TritonX-100) corresponding to the animal the secondary antibody was
raised in, with washes in 1X PBS between each step. Permeabilized cells were incubated with
primary antibody overnight at 4°C (ab92494, AbCam, 1:100 in 1% BSA and 0.3% TritonX-100),
washed with 1X PBS, and incubated in secondary antibody for 2 hours at room temperature (antirabbit-IgG-FITC, F0382, Sigma, 1:500 in 1% BSA and 0.3% TritonX-100). Cells were also
incubated with Hoeschst dye (33258, Fisher) at 2 µg/ml in 1X PBS for 3 min.
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CHAPTER 3:

Musashi2 is required for the self-renewal and pluripotency of
embryonic stem cells

The studies described in this chapter, which were conducted
by Erin Wuebben, are described in two studies [80, 96].
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3.1

Introduction
Sox2 is required during mammalian embryogenesis and it plays critical roles in the self-

renewal and pluripotency of ESC. SOX2 expression also influences the growth of brain tumor
cells. Previous studies in our laboratory used unbiased proteomic screens to identify nuclear
proteins that associate with Sox2 in ESC undergoing early stages of differentiation, as well as in
MB and GBM brain tumor cells [80, 82]. Remarkably, Sox2 associates with >60 proteins during
the early stages of differentiation and >280 in DAOY MB cells that participate in a diverse range
of cellular processes; one of these Sox2-associated proteins identified in both networks is the
RNA binding protein Musashi 2 (Msi2), which also associates with SOX2 in GBM. As discussed
in the Introduction of this dissertation, Msi2 has been shown to play important roles in
development. Specifically, Msi2 has been shown to contribute to the development of the nervous
system, along with Msi1, and they have been shown to work together to promote the maintenance
of neural stem cells [101]. Msi2 has also been shown to be elevated in several leukemias such as
CML and AML and its elevated expression has been linked with poorer prognosis in these
cancers [100, 103, 192]. Given the contribution of Msi2 to tumorigenicity, its roles during
development, and its association with Sox2 in ESC and brain tumor cells we predicted that MSI2
plays essential roles in cells where SOX2 and MSI2 associate with one another. Specifically we
predicted that proteins that associate with SOX2 in multiple SOX2-dependednt cell types must
also be essential in those cells.

3.2

ESC express and require Msi2
To study the role of Msi2 in mouse ESC, we initially examined whether ESC express

more than one isoform of Msi2. Studies in other systems [98, 193] identified two isoforms of
Msi2: isoform 1 (full length) consisting of 346 amino acids and isoform 2 consisting of 328
amino acids (Figure 3.1A). Using primers specific to Msi2 isoform 1 and isoform 2, we
determined that D3 ESC express both isoforms of Msi2 at the RNA level (Figure 3.1B). In
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addition, we determined by western blot analysis that ESC express both isoforms of Msi2 at the
protein level (Figure 3.1C).
To investigate the role of Msi2 in ESC, we examined how ESC would be affected by the
knockdown of Msi2. For this purpose, we used lentiviral vectors that express shRNA directed at
both isoforms (shRNA #1 and shRNA #5) and only isoform 1 (shRNA #4) (Figure 3.2A).
Specifically targeting isoform 2 will be more difficult, as isoform 2 shares the entirety of its
sequence with isoform 1, differing only through an omission of a small region. Thus, to target
isoform 2, an shRNA sequence will need to bridge the region that is spliced out from isoform 1.
As a control, we also infected ESC with a lentivirus that expresses a scrambled shRNA sequence,
which we previously determined does not influence the behavior of D3 ESC [97]. Initially, we
examined the knockdown of Msi2 by comparing the protein levels of Msi2 in ESC infected with
the lentiviral vector that expresses the scrambled shRNA control with the levels of Msi2 in cells
infected with lentiviral vectors that express shRNA #1, #4 or #5. We determined that infection of
ESC with the lentiviral vector that expresses shRNA #1 caused a significant reduction in both
isoforms of Msi2, and infection of ESC with the lentiviral vector that expresses #4 caused a
significant reduction in Msi2 isoform 1, but not isoform 2 (Figure 3.2B). In contrast, the lentiviral
vector that expresses shRNA #5 appears to induce only a modest reduction in isoform 1 (~30%)
and small reduction in isoform 2 (~10%).
Examination of the infected cells by light microscopy indicated that ESC infected with
the control lentiviral vector, which expresses the scrambled shRNA sequence, did not induce
morphological changes in the cells. In contrast, lentiviral vectors #1 and #4 caused extensive
morphological differentiation (Figure 3.2C). As expected from the effects on Msi2 protein
expression (Figure 3.2B), lentiviral vector #5 caused significantly less differentiation. To further
characterize the observed change in morphology, we stained cells infected with the various
shRNA constructs with alkaline phosphatase (AP), a cell-surface marker associated with
pluripotency. Reduced AP-staining intensity in ESC infected with Msi2 shRNA constructs #1 and
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#4 corroborated our observation that knockdown of Msi2 impairs the ability of ESC to self-renew
(Figure 3.2C). To determine whether the differentiation observed was due to a loss in essential
pluripotency factors, we conducted western blot analysis to examine the levels of Sox2 and Oct4
following the knockdown of Msi2. Interestingly, the levels of Sox2 and Oct4 were not
significantly altered after the knockdown of Msi2 (Figure 3.2D).
To quantitate the extent of differentiation induced by the knockdown of Msi2, virally
infected cells were plated at clonal density. Six days later, colonies were scored by an observer
unaware of sample designation as ES cell colonies, differentiated colonies or mixed colonies
consisting of both ESC and differentiated cells. Typical of unmodified ESC, a high percentage of
D3 ESC expressing the scrambled shRNA formed ES cell colonies (~80%) and relatively few
mixed and differentiated colonies (Figure 3.3). In contrast, D3 ESC infected with lentiviral
vectors expressing either shRNA #1 or shRNA #4 formed far fewer ES cell colonies (<15% in the
case of shRNA #4) and a large percentage of mixed and differentiated cell colonies. In addition,
shRNA #5 only modestly reduced the number of ES cell colonies (by ~40%) and increased the
number of mixed and differentiated colonies. Importantly, our studies show that the extent of
differentiation and the loss of self-renewal capacity correlate with the level to which Msi2 levels
were decreased. Equally importantly, our studies indicate that the knockdown of isoform 1
induces the differentiation of ESC. Studies discussed below suggest that the self-renewal of ESC
may also require expression of Msi2 isoform 2.

3.3

Msi2 knockdown alters gene expression
To further characterize the differentiation of ESC following the knockdown of Msi2, we

initially examined the changes in gene expression by microarray analysis. Changes in global
RNA expression were determined by comparing the RNA expression profiles of ESC that express
either the scrambled shRNA or shRNA #1 by microarray. Of 29,000 transcripts examined, we
determined that cells infected with Msi2 shRNA #1 exhibited increased expression of 40 genes
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≥2.5-fold (Table 3.1) and decreased expression of 29 genes ≥ 2.5-fold (Table 3.2) compared to
cells infected with scrambled shRNA. Broadening our parameters to genes whose expression
increased or decreased by ≥ 2-fold (Figure 3.4A, Tables 3.3 and 3.4) expanded these subsets with
an additional 49 and 46 genes, respectively. Gene ontology analysis (Figure 3.4B) indicated that a
large percentage of the genes that exhibited >2-fold increased gene expression play roles in cell
signaling (e.g. Tspan2, Irs2, Sfrp2, Ctgf) and cellular structure (e.g. Acta2, Actc1, Cald1, Myl9);
whereas, genes that exhibited >2-fold decrease in expression participate in development (e.g.
Amot, Pdgfr, Lama1) and metabolism (e.g. Nostrin, Nrg1, Inhbb). Given the morphological
changes that accompany differentiation, in particular the increase in cytoplasmic to nuclear ratio,
increases in genes associated with cellular structure is not surprising. Similarly, the large change
in the expression of genes associated with metabolic processes when Msi2 is knocked down
parallels the large changes in metabolic gene expression when somatic cells are reprogrammed to
induced pluripotent stem cells [194]. A complete list of the differentially expressed genes and
their associated ontologies are provided in a heatmap [96].
To validate our microarray analysis, 23 genes were examined more closely using RTqPCR, which is a more quantitative approach to examine transcript expression. For this analysis,
we examined a number of genes that increased or decreased according to our microarray data, and
a number of genes critical for maintaining pluripotency in ESC. In concordance with our
microarray data, analysis by RT-qPCR indicates that a number of genes associated with
mesoderm development (Tpm1, Tagln, Brachyury, MyoD1), ectoderm development (Pax6,
Nestin) and trophectoderm development (Cdx2, Esx1) were elevated when Msi2 was knocked
down (Figure 3.5). Additionally, a number of markers associated with endoderm development
(Gata6, Sox17, Gata4, Sox7) were reduced as determined by both our microarray and RT-qPCR
(Figure 3.5). We also examined the expression of Numb and Msi1 mRNA by RT-qPCR, both of
which exhibited a small increase when Msi2 was knocked down. The small increase in Msi1
mRNA may reflect a compensatory mechanism that coordinates the expression of Msi1 and Msi2.
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3.4

Msi2 enhances the cloning efficiency of ESC
Because of our observation that the knockdown of Msi2 leads to the loss of self-renewal

in ESC, we examined whether the elevation of Msi2 would enhance the self-renewal of ESC.
Recent studies have shown that elevating Msi2 helps in the maintenance of hematopoietic and
tumor stem cells [100, 102, 103]. However, it was not clear whether Msi2, in particular isoform 1
or isoform 2 could enhance ESC self-renewal. To examine this possibility, we engineered ESC
for Dox-inducible overexpression of Flag-tagged Msi2, as described in the Methods section.
Briefly, D3 ESC were infected with a lentivirus that constitutively expresses the reverse tet
transactivator (rtTA), which binds Dox to mediate inducible transgene expression. These cells
were then infected with a second lentivirus that expresses either Flag-tagged Msi2 isoform 1 (iMsi2.1-D3 ESC) or isoform 2 (i-Msi2.2-D3 ESC) when the cells are exposed to Dox.
Using this system, we determined that addition of Dox leads to a small increase (~1.8
fold) in Flag-Msi2-isoform 1 (Figure 3.6A, left) and increases the cloning efficiency of ESC,
specifically the number of ES cell colonies that form (Figure 3.6B, left). Conversely, ~2-fold
overexpression of Flag-Msi2-isoform 2 (Figure 3.6A, right) in i-Msi2.2-D3 ESC had no
significant effect on cloning efficiency, in particular the number of ES cell colonies that formed
(Figure 3.6B, right). As a control, D3 ESC engineered for the inducible expression of luciferase
did not demonstrate significant changes in the distribution of colony morphologies upon the
addition of Dox (data not shown).

3.5

Msi2 isoform 1 or Msi2 isoform 2 on their own do not rescue the knockdown of both

isoforms of Msi2
Our initial experiment in which shRNA #4 was used to target only isoform 1 suggested
that Msi2 isoform 2 may not be required to support the self-renewal of ESC (Figure 3.2). This
finding, coupled with the observation that Msi2 isoform 1 enhances the self-renewal of ESC, led
us to examine whether isoform 1 alone is sufficient to support the self-renewal of ESC.
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To determine whether Msi2 isoform 1 is sufficient to support ESC self-renewal, i-Msi2.1D3 ESC and i-Msi2.2-D3 ESC were cultured in the absence or presence of Dox (2 µg/mL) for 24
hours. Next, the cells cultured in the presence or absence of Dox were infected with Msi2 shRNA
#1 lentivirus, which targets both isoforms of Msi2 on their 3’ UTR. Cells pretreated with Dox
were cultured in the presence of Dox for the entire experiment. Western blot analysis of proteins
isolated from i-Msi2.1-D3 ESC verified that total Msi2 levels were reduced (~60%) in cells
cultured in the absence of Dox; whereas, total Msi2 levels were near normal (~90%) when the
infected cells were maintained in the presence of Dox, due in part to exogenous expression from
the transgene (Figure 3.7A). Additionally, in i-Msi2.2-D3 ESC infected with shRNA #1, Msi2
levels were knocked down (~60%, relative to endogenous Msi2) in the minus Dox control, but
elevated ~2-fold when cultured in the presence of Dox (Figure 3.7B). The reason for the intensely
staining band observed at the level of Msi2 isoform 2 in i-Msi2.2-D3 ESC cultured in the
presence of Dox is not completely clear. We suspect that this is due to alternative translation start
from our exogenous Flag-Msi2 isoform 2 transcript, which retains the endogenous Msi2 start
codon.
To quantify any changes in self-renewal efficiency, i-Msi2.1-D3 ESC and i-Msi2.2-D3
ESC expressing their respective isoforms of Msi2 and infected with Msi2 shRNA #1 were
subcultured 72 hours after infection with shRNA lentivirus, and plated at clonal density. Our
findings indicate that elevation of Msi2 isoform 2 did not block the differentiation of ESC
following the knockdown of both isoforms of Msi2 (Figure 3.7C). Interestingly, isoform 1 was
also unable to block the differentiation of ESC following the knockdown of Msi2 (Figure 3.7C).
Thus, our data suggests that the expression of isoforms 1 and 2 are both necessary to support the
self-renewal of ESC.

3.6

Elevation of Msi2 during differentiation does not bias differentiation
Because of the role of Msi2 in hematopoietic stem cell maintenance and neural
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development, we examined whether induction of Msi2 could skew the differentiation of ESC
toward specific developmental lineages. For this purpose, i-Msi2.1-D3 and i-Msi2.2-D3 ESC,
expressing their respective forms of Msi2, were differentiated using retinoic acid (RA). More
specifically, i-Msi2.1-D3 and i-Msi2.2-D3 ESC were cultured continuously in the absence or
presence of Dox. Two days after the addition of Dox to cells, RA was added to the culture
medium, and cells were allowed to grow an additional 4 days. After treatment of cells with RA
for 4 days (with and without Dox), RNA was isolated and examined by RT-qPCR analysis as
described in the Methods. As expected, the pattern of differentiation induced by RA in the
absence of Dox was highly similar for i-Msi2.1-D3 and i-Msi2.2-D3 ESC. More importantly,
treatment of these ESC with Dox, which induces ectopic expression of Msi2 isoform 1 and Msi2
isoform 2, respectively (Figures 3.6 and 3.7), did not alter the pattern of RA-induced
differentiation (Figure 3.8).

3.7

Musashi2 is necessary for the proliferation of DAOY MB cells
Previous reports demonstrated that MSI2 is essential for the progression of CML [100,

103, 192], and the knockdown of another family member, Musashi1 (MSI1), disrupts the viability
of DAOY MB cells and GBM cells [195, 196]. To determine whether MSI2 is necessary for the
proliferation of DAOY MB cells, shRNA constructs were used to knock down endogenous MSI2.
Specifically, lentiviruses that constitutively express shRNA against MSI2 were used to infect
DAOY MB cells. Two independent shRNA constructs (described in Chapter 2 of this
dissertation) were used to knockdown MSI2, and a previously characterized non-specific shRNA
(Scrambled) was used as a control [97, 184]. Following selection of the infected cells with
puromycin, western blot analysis demonstrated that MSI2 isoforms 1 and 2 were substantially
knocked down (Figure 3.9A). This reduction in MSI2 was verified at the RNA levels by RTqPCR (Figure 3.10A). In addition, when compared to the growth of DAOY cells infected with
the Scrambled shRNA lentiviral vectors, we observed a large reduction in growth when the cells
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were infected with MSI2 shRNA lentiviral vectors (Figure 3.9B). Moreover, photomicrographs
taken 7 days after infection demonstrated that cells in which MSI2 had been knocked down were
flatter and larger, reminiscent of post-mitotic cells, when compared to the Scrambled control
(Figure 3.9C).
Currently, relatively little is known about the roles of MSI2, but in mouse model of
leukemia it is believed to down-regulate the protein Numb [103], which has been shown to
regulate both Notch and Wnt signaling [197, 198]. Therefore, we examined whether knockdown
of MSI2 in DAOY cells influences the expression of NUMB. We determined that knockdown of
MSI2 with shRNA lentiviral vectors #4 and #5 caused an increase in the protein levels of NUMB
(Figure 3.9D). Thus, knockdown of MSI2 causes both a large reduction in the growth of DAOY
MB tumor cells and increases the expression of NUMB.

3.8

Musashi2 is necessary for the proliferation of GBM cells
We also examined the consequences of knocking down MSI2 in GBM tumor cells,

because MSI2 was also identified as a SOX2-associated protein in U87 GBM cells (Wilder and
Rizzino, unpublished results). For this purpose, we initially infected U87 GBM tumor cells with
the same MSI2 shRNA lentiviral vectors described earlier. Again, a scrambled shRNA was used
as a control. Three days after infection with the lentiviral vectors, western blot analysis
determined that MSI2 isoform 1 and isoform 2 were both substantially reduced (Figure 3.11A)
and the reduction in MSI2 was verified at the RNA levels by RT-qPCR (Figure 3.10B). As in the
case of DAOY cells, U87 GBM cells infected with MSI2 shRNA constructs exhibited a marked
decrease in cell proliferation (Figure 3.11B) and a significant increase in cell size (Figure 3.11C).
To extend these findings, U118 GBM cells were infected with MSI2 shRNA lentiviruses. Similar
to DAOY and U87 cells, knockdown of MSI2 in U118 cells resulted in a decrease in MSI2
protein and RNA, a large reduction in cell growth, and a significant increase in cell size (Figure
3.10C and Figure 3.12). Taken together, our data indicate that MSI2 is required to sustain the
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survival of DAOY MB cells, and the proliferative capacity of U87 and U118 GBM cells.

3.9

Discussion
In this study, we demonstrate that ESC express two isoforms of Msi2, and we determined

that the knockdown of Msi2 disrupts the self-renewal of ESC and induces their differentiation.
Moreover, our studies demonstrate that the extent of differentiation and the loss of self-renewal
capacity correlates with the extent to which Msi2 levels were decreased. Remarkably, the
knockdown of Msi2 causes ESC to differentiate despite continued expression of both Sox2 and
Oct4.
Although knockdown of Msi2 isoform 1 is sufficient to induce the differentiation of ESC
(Fig. 3.2 shRNA #4), a more rigorous demonstration that ESC strictly require Msi2 isoform 2 will
require considerably more work. The most direct method for addressing this question would be to
selectively knockdown Msi2 isoform 2. As mentioned earlier, addressing this question will
require an shRNA that only targets isoform 2, which is currently not available. Thus far, this
question has not been addressed in any study, including the recent reports that demonstrated
prominent roles of Msi2 in the function HSC, CML, and AML [100, 102, 103]. In these seminal
studies, the shRNA sequences used targeted both isoforms of Msi2.
We also determined that overexpression of Msi2 isoform 1, but not isoform 2, enhances
the cloning efficiency of ESC, which is a measure of their self-renewal capacity. However, we
determined that ectopic expression of either Msi2 isoform 1 or isoform 2 does not block the
differentiation of ESC when both isoforms of Msi2 are knocked down. Moreover, ectopic
expression of Msi2 isoform 1 or isoform 2 does not appear to alter the pattern of differentiation
induced by the treatment of ESC with RA. Thus, our findings suggest that both isoforms of Msi2
are required to maintain the self-renewal of ESC.
Finally, the studies presented in this Chapter support that MSI2 is required for the
proliferation of medulloblastoma cells as well as glioblastoma cells. Although several SOX2-
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associated proteins have been implicated in brain cancer, the roles of the vast majority of SOX2associated proteins have not been examined in brain cancer. In this Chapter, we examined the
SOX2-associated protein MSI2, which has been implicated in supporting the growth of other
cancers. Knockdown of MSI2 in MB and GB cells impairs their ability to proliferate. Currently, it
is unclear why the knockdown of MSI2 reduces the growth of brain tumor cells. Recent studies
suggest that the translation of NUMB mRNA, which is a known target of MSI1 [99], inversely
correlates with MSI2 expression in leukemia [192]. Interestingly, we observed an increase in the
level of NUMB when MSI2 was knocked down in DAOY cells. Moreover, others have reported
that overexpression of NUMB in DAOY cells reduces their colony-forming ability [199]. Thus, it
is tempting to speculate that knockdown of MSI2 reduces the viability of DAOY cells because of
the increase in NUMB. However, further study will be needed to verify whether this is in fact the
case, because MSI2 is likely to affect the expression of other important genes. In this regard,
studies conducted in HEK293T cells identified >60 mRNA that associate with MSI1 [200].
Hence, MSI2 is also likely to regulate the translation of a significant number of mRNA. The
reason for the reduction in the proliferation of U87 and U118 GB cells when MSI2 is knocked
down is also unclear. Recently, it has been reported that elevating NUMB in U87 cells does not
affect their proliferation [201]. Thus, further study will be needed to define the roles of MSI2 in
brain tumor cells. Importantly, the studies described in this Chapter substantiate our belief that
identifying proteins that interact with SOX2 in multiple cellular contexts is a useful approach for
identifying critical understudied proteins for diseases such as cancer.
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CHAPTER 4:

SOX2 functions as a molecular rheostat in pancreatic ductal
adenocarcinoma

The studies described in this chapter, which were conducted
by Erin Wuebben, and are published in Oncotarget [202].
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4.1

Introduction
PDAC is presently one of the most lethal malignancies in the United States, as outlined in

Chapter 1 of this dissertation, and SOX2 expression has been shown to increase as PDAC
progresses. More recent studies reported that SOX2 is expressed in many different human PDAC
cell lines, with high expression in some PDAC cell lines, but little or no expression in others
[155]. Importantly, this study demonstrated that SOX2 expression is closely associated with
putative cancer stem cell markers previously reported to be expressed by PDAC tumor-initiating
cells [155]. This study also demonstrated that knocking down SOX2 in PDAC cell lines reduced
their growth in vitro; whereas, stable expression of SOX2 in a PDAC cell line, which does not
endogenously express detectable levels of SOX2, increased their anchorage-independent growth
[155]. Although this study provided support in vitro for a critical role of SOX2 in the stemness of
PDAC, the effects of SOX2 on the tumorigenicity of PDAC tumor cells were not examined.
Here, we examined the growth responses of multiple PDAC cells lines engineered for
either inducible overexpression of SOX2 or inducible knockdown of SOX2. In addition to
examining how altering SOX2 expression influences PDAC cell growth in vitro, we examined
how tumorigenicity is affected when SOX2 levels are increased and decreased.

4.2

Engineering PDAC Cell Lines for SOX2 Overexpression
To determine how elevating the levels of SOX2 influences the behavior of PDAC cells,

we initially engineered T3M4 PDAC cells for inducible overexpression of epitope-tagged SOX2.
Epitope-tagged SOX2 enabled us to distinguish exogenously expressed SOX2 from endogenous
SOX2. SOX2 was tagged at its N-terminus with a sequence that codes for a Flag-Strep tag.
Previous studies have shown that placement of this tag at the N-terminus does not interfere with
its function [80, 87, 93, 172, 203]. T3M4 cells were selected because they express SOX2 at
intermediate levels, ~15-fold lower than L3.6 cells (data not shown), which have been shown
previously to express SOX2 at levels significantly higher than most other PDAC cell lines [155].
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Additionally, L3.6 cells express mutant KRAS (G12D) [204]; whereas, T3M4 cells
heterozygously express a different KRAS mutant (Q61H/WT) [205]. Using T3M4 cells, we could
determine how both inducible overexpression of SOX2, as well as inducible knockdown of SOX2
(see below), influences the behavior of PDAC cells. T3M4 cells were engineered for inducible
overexpression with the aid of two lentiviral vectors, which are similar to those used previously to
engineer brain tumor cells for inducible expression of exogenous SOX2 [172]. One lentiviral
vector codes for the expression of the reverse tet-transactivator driven by a PGK promoter, and
the second lentiviral vector codes for the expression of epitope-tagged SOX2, which is driven by
a Dox-inducible promoter (Figure 2.1). After viral transduction of T3M4 cells, cells stably
transduced with both lentiviral vectors were isolated as described in Chapter 2. These cells are
referred to as i-SOX2-T3M4 cells.

4.3

Overexpression of SOX2 Reduces PDAC Cell Growth in vitro and in vivo
To determine how inducible elevation of SOX2 influences the in vitro growth of i-SOX2-

T3M4 cells, we initially examined a Dox-dose response curve. As the concentration of Dox was
increased, there was a dose dependent increase in the expression of Flag-SOX2. At 300 ng/ml of
Dox there was a ~7.5-fold increase in total SOX2 (endogenous plus exogenous SOX2) (Figure
4.1A). Treatment of i-SOX2-T3M4 cells with Dox over a 4 day period led to decreased cell
growth at all Dox concentrations tested, reaching nearly 40% reduction in cell proliferation at 300
ng/ml of Dox (Figure 4.1B). A significant reduction in cell growth was evident after 72 hr (not
statistically different at 48 hr, Figure 4.1C). As a control, we tested the effects of Dox on parental
T3M4 cells. At concentrations as high as 1 µg/ml, there were no effects on the growth of parental
T3M4 cells (Figure 4.1B). To extend these studies, we assessed the effects of elevating SOX2 on
the clonal growth of i-SOX2-T3M4 cells in both monolayer culture and under anchorageindependent growth conditions. When plated at clonal densities in monolayer culture, inducible
overexpression of SOX2 after 8 days significantly reduced the number of colonies, as well as the
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size of the colonies (Figure 4.1D). Importantly, even after repeated passage in the presence of
Dox (> 10 passages), we failed to observe the emergence of cells that exhibited accelerated
growth due to elevation of SOX2. After each passage, there was a reduction in the growth of cells
treated with Dox when compared to cells cultured in the absence of Dox (data not shown). Not
surprisingly, inducible elevation of SOX2 also failed to increase the growth of i-SOX2-T3M4
cells under anchorage-independent growth conditions. After treatment with Dox for 9 days in
serum-free, stem cell medium, the number and size of the colonies formed in soft-agar was
reduced significantly (Figure 4.1E). Under these conditions, there was a reduction in the total
number of colonies, where the largest reduction was in the number of large colonies.
To determine whether the effects of SOX2 overexpression were PDAC cell line
dependent, we engineered two additional PDAC cell lines, BxPC3 and HPAF-II, for inducible
overexpression of SOX2. BxPC3 cells endogenously express SOX2 at levels ~5-fold higher than
T3M4 cells; whereas, HPAF-II cells express endogenous SOX2 at levels lower than T3M4 cells
(data not shown). HPAF-II cells express activated, mutant KRAS (G12D) [206]; whereas, BxPC3
cells express wild-type KRAS [207, 208]. Thus, BxPC3 cells could help determine whether the
effects of inducible overexpression of SOX2 were related to the KRAS status of PDAC cells.
BxPC3 cells and HPAF-II cells were each transduced with the same lentiviral vector set (Figure
2.1) used to engineer T3M4 cells. As shown for i-SOX2-T3M4, we observed tunable induction of
exogenous SOX2 when i-SOX2-HPAF-II cells and i-SOX2-BxPC3 were exposed to increasing
concentrations of Dox (Figure 4.2A, D). In addition, at all Dox concentrations tested, elevation of
SOX2 in i-SOX2-HPAF-II and i-SOX2-BxPC3 cells reduced both their short-term monolayer
growth and their growth at clonal density (Figure 4.2B, C, E, and F). Elevating SOX2 in i-SOX2HPAF-II, led to ~40% reduction in growth (Figure 4.2E). In the case of i-SOX2-BxPC3 cells,
reduction in growth was smaller, but statistically significant Figure 4.2B). Importantly, under no
conditions examined did we observe an increase in proliferation when SOX2 levels were elevated
in three different PDAC cell lines. Altogether these studies demonstrate that inducible
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overexpression of SOX2 in PDAC cells reduces their growth in vitro.

4.4

SOX2 Overexpression Decreases Subcutaneous Tumor Growth
A key property of cancer cells is tumorigenicity. To assess the impact of overexpression

of SOX2 on the tumorigenicity of PDAC cells, 2.5x105 i-SOX2-T3M4 cells were engrafted
subcutaneously into NCr-nu/nu mice, as described in Chapter 2. Nine days after palpable tumors
had formed, sized-matched tumors were randomly assigned to the control or the Dox-treated
group. After 9 additional days, tumors in the control group (11 mice) had grown to an average >
450 mm3; whereas tumors in the Dox-treated group (11 mice) exhibited much less growth,
reaching on average ~90 mm3 (~80% smaller, p<0.001) (Figure 4.3A). In addition, tumor weight
was reduced ~70% in the Dox-treated group (Figure 4.3B). There was also ~2-fold increase in
fraction of the tumor consisting of desmoplastic stroma relative to that observed in the control
tumor group, which were not treated with Dox, as determined by smooth muscle actin (SMA)
staining (p<0.05, Figure 4.3D). Interestingly, the proliferation marker Ki-67 was ~75% lower in
the tumor cell compartment of the Dox-treated tumors compared to untreated tumors (p<0.01);
whereas, Ki-67 staining was ~2-fold higher in the stromal compartments of Dox-treated tumors
compared to untreated tumors (p<0.05, Figure 4.3E). Altogether, our findings argue that inducible
overexpression of SOX2 in PDAC cells does not increase cell growth, but, in fact, reduces their
growth in culture as well as their tumorigenicity.

4.5

Knockdown of SOX2 Decreases PDAC Cell Growth in vitro and in vivo
We also assessed the impact of knocking down SOX2 on the growth and tumorigenicity

of T3M4 cells. For this purpose, T3M4 cells were transduced with a single lentiviral vector that
codes for an inducible promoter driving expression of a SOX2 shRNA, as well as coding for
constitutive expression of the reverse tet-transactivator that is capable of binding to the Doxinducible promoter when Dox is added to the culture medium. Productively transduced T3M4
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cells, referred to as i-KdSOX2-T3M4 cells, were isolated as described in Chapter 2. Treatment of
these cells with increasing concentrations of Dox led to dose dependent reductions in the
expression of endogenous SOX2 protein (Figure 4.4A) and dose dependent reductions in cell
growth (Figure 4.4B). After 3 days of growth, there was a statistically significant reduction of
growth, reaching >50% inhibition after 4 days (Figure 4.4C) when SOX2 was reduced ~60%
(Figure 4.4A). As discussed below, treatment with Dox at this concentration also reduced the
number of colonies as well as the size of colonies when plated at clonal density in monolayer
culture. Additionally, a second, independent shRNA lentiviral vector was used in T3M4 cells to
validate that observed effects were due to the knockdown of SOX2. As described above,
increasing the concentration of Dox resulted in dose-dependent reductions in SOX2 protein
expression and in cell growth after 4 days when using this second shRNA vector; however, this
shRNA was less effective at knocking down SOX2 (~40% reduction) and less effective at
reducing growth (<30%, Figure 4.5). Thus, in the studies described below, the cells engineered
with the first SOX2 shRNA were used.
Additionally, we examined whether knocking down SOX2 in another PDAC cell line
would also alter their growth. For this purpose, L3.6 cells, which express high levels of SOX2,
were transduced with the same Dox-inducible SOX2 shRNA lentiviral vector used to generate iKdSOX2-T3M4 cells. Treatment of i-KdSOX2-L3.6 cells with increasing concentrations of Dox
led to a dose dependent decrease in the expression of SOX2 protein and a decrease in the growth
of the cells in monolayer culture (Figure 4.4D-F).
Next, we assessed the impact of knocking down SOX2 on the tumorigenicity of iKdSOX2-L3.6 cells. i-KdSOX2-L3.6 cells were engrafted subcutaneously into NCr-nu/nu mice.
Once palpable tumors had formed by engrafted i-KdSOX2-L3.6 cells, mice with sized-matched
tumors were randomly assigned to the control or the Dox-treated group. After an additional 8
days, the tumors in the control group increased from an average of 20 mm3 to an average of 230
mm3; whereas tumors in the Dox group increased from an average of 20 mm3 to an average of 70
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mm3 – a reduction of ~70% (Figure 4.6A). Immunohistochemical staining for the proliferation
marker Ki-67 was reduced ~50% in the tumor cell compartment of the Dox-treated tumors
compared to untreated tumors (p<0.05, Figure 4.6C-E). In a smaller study, i-KdSOX2-T3M4
cells were engrafted subcutaneously into NCr-nu/nu mice. Once palpable tumors had formed by
engrafted i-KdSOX2-T3M4 cells, mice with sized-matched tumors were randomly assigned to the
control or the Dox-treated group. After an additional 16 days, the tumors in the control group
increased from an average of 50 mm3 to an average of 330 mm3; whereas tumors in the Dox
group increased from an average of 70 mm3 to an average of 135 mm3 (Figure 4.7). While this
small study was not statistically significant, is does lend credence to the previous study with iKdSOX2-L3.6 cells in which similar results were seen. Altogether, our studies demonstrate that
either increasing SOX2 (Figure 4.3) or decreasing SOX2 reduces the growth of tumors. Thus, the
tumorigenicity of these cells is highly dependent on the expression of optimal levels of SOX2.

4.6

Summary
As discussed in the Introduction of this dissertation, SOX2 levels have been studied in

many different cancer types, with variable results. In this study, we demonstrate that inducibly
either increasing or decreasing levels of SOX2 in PDAC cells reduces growth both in vitro and in
vivo. Prior to the work described here, stable overexpression of SOX2 in a PDAC cell line had
been shown to increase cell proliferation in vitro. We reexamined the role of SOX2 in PDAC,
because we had previously determined that inducible elevation of SOX2 in various types of tumor
cells leads to growth inhibition rather than growth promotion [172]. Importantly, the work
described here demonstrates that this is also true for PDAC cells. Specifically, we demonstrate
that inducible elevation of SOX2 in three different PDAC cell lines in vitro leads to growth
inhibition, rather than growth stimulation. We also determined that increases in SOX2 lead to a
reduction in tumorigenicity. Under no conditions was growth observed to increase when SOX2
levels were elevated from an inducible promoter.
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Although inducible elevation of SOX2 leads to PDAC growth inhibition in vitro as well as a
substantial reduction in tumor growth, this does not indicate that SOX2 plays little or no role in
promoting the growth of PDAC. Previous studies had shown that knockdown of SOX2 in four
different PDAC cells lines reduces growth in vitro [155]. In the work presented here, we not only
demonstrate that knockdown of SOX2 reduces growth in vitro; we also demonstrate that tumor
growth of i-KdSOX2-L3.6 cells is reduced when SOX2 is knocked down in vivo. Thus, SOX2 is
clearly required for the growth of PDAC both in vitro and in vivo. Equally important, our studies
indicate that endogenous levels of SOX2 in PDAC cells are optimized for maximum growth, as
both increases and decreases in SOX2 reduce PDAC cell growth. Hence, SOX2 functions as a
biphasic molecular rheostat in the control of PDAC cell proliferation. Coupled with our
demonstration that this is also true for ES cells [17] and four other tumor cell types [172], we
suggest that this is a defining feature of SOX2. Going forward, it will be essential to gain a much
deeper understanding of how SOX2 influences the growth of PDAC, and the genetically
engineered PDAC cell lines described in this dissertation should provide a highly useful platform
for addressing this question.
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CHAPTER 5:

Inducible modulation of SOX2 levels alters the efficacy of drugs
used clinically

The studies described in this chapter, which were conducted
by Erin Wuebben, and are published in Oncotarget [202].
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5.1

Introduction
SOX2 has been implicated in drug resistance in a number of cancers including

glioblastoma, bladder, breast, gastric, head and neck, lung, ovarian, and prostate cancers [129,
137, 141, 142, 151, 152, 154, 158, 163, 168, 169]. As described in Chapter 4, SOX2 levels must
be tightly regulated to maintain the growth of PDAC cells in vitro and in vivo, but no studies have
examined the effects of SOX2 on drug resistance in pancreatic cancer. The Introduction of this
dissertation outlined the desperate need to identify new therapeutic targets for PDAC as current
therapeutics have yet to improve the high mortality rate for patients with PDAC. Many genes and
signaling pathways have been shown to be aberrantly activated in PDAC; the most common of
these is a constitutively activated KRAS mutation. Tumors with KRAS mutations are highly
dependent on upregulated AKT and RAF/MEK/ERK signaling, which are downstream of KRAS
[179-182], and thus, a variety of PDAC clinical trials have tested AKT inhibitors (AKTi), e.g.
MK-2206, and at least five MEK inhibitors (MEKi), e.g. trametinib [183]. Disappointingly, these
drugs have not produced significant responses in PDAC clinical trials, which has led to the
general belief that PDAC is largely resistant to AKTi and MEKi. Given the association reported
for SOX2 and drug resistance in several other cancers, in the following studies we examined how
changes in the levels of SOX2 influence the responses of PDAC cells to MEKi and AKTi used in
clinical trials.

5.2

Inducible Elevation of SOX2 Alters Cell Cycle Effects in the Presence of MEKi
To begin to understand the impact of altering SOX2 levels on the growth responses of

PDAC cells to drugs used in PDAC clinical trials, we initially examined how elevating SOX2
influences the cell cycle of i-SOX2-T3M4 cells when treated with five MEKi that have been, or
that are currently, used in PDAC clinical trials. For this purpose, we initially determined the
EC50 for each MEKi exhibited by i-SOX2-T3M4 cells based on the reduction in growth over a 4
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day period (Table 2.1). Additionally, we confirmed the suppression of ERK1/2 phosphorylation
when MEKi are used at their EC50 (Figure 5.1). When used at their respective EC50, each of the
MEKi led to a sizable increase in the G1 population of the cells and a sizable decrease in S-phase
after 48 hr (Figure 5.2). As expected, elevating SOX2 by treatment with Dox also altered the cell
cycle of i-SOX2-T3M4. However, there was only a modest increase in G1 and a modest decrease
S-phase. Remarkably, when the cells were treated simultaneously with Dox and any of the five
MEKi, we observed a partial reversal of the cell cycle changes observed with each MEKi on its
own. More specifically, the increase in G1 and the reduction of S-phase observed with the MEKi
was partially reduced when SOX2 levels were elevated in the cells (Figure 5.2A). Interestingly,
each of the five MEKi induced pronounced morphological changes exemplified by significant
cell spreading, and this effect was also partially reversed when SOX2 was inducibly elevated
(Figure 5.2B).

5.3

Elevation of SOX2 Partially Reverses the Reduction in Clonal PDAC Growth Due to

Treatment with Trametinib
To more carefully assess the effects of elevating SOX2 on the growth responses of PDAC
cells when treated with MEKi, we examined the clonal growth of i-SOX2-T3M4 cells cultured in
the presence of one of the MEKi (trametinib) with and without Dox. For this purpose, 24 hr after
the cells had been subcultured, trametinib and/or Dox were added to the cells where indicated.
During the following 8 days, the cells were refed with fresh medium containing trametinib and/or
Dox every other day. After 8 days of treatment, the number of colonies formed when the cells
were treated with trametinib at its EC50 was significantly reduced. However, treatment with both
trametinib and Dox led to a much smaller reduction in colony number (Figure 5.3). As a control,
we determined that treatment of parental T3M4 cells with Dox did not affect the dose response
curves of trametinib or a second MEKi, selumetinib (data not shown).
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5.4

Replating Efficiency of Trametinib-treated PDAC Cells is Improved by SOX2

Elevation
To further evaluate the effects of trametinib on i-SOX2-T3M4 cells, the cells were
cultured for 6 days at typical cell culture densities (1.2x104/cm2) in the presence of trametinib
with or without Dox. After 6 days, cells treated with trametinib or trametinib plus Dox both
exhibited a change in morphology (Figure 5.4A) relative to untreated i-SOX2-T3M4 cells (Figure
5.2B), but the cells treated with trametinib on its own exhibited the most pronounced
morphological change. Next, the trametinib treated and the trametinib plus Dox treated cells were
subcultured and replated at clonal densities in the absence of trametinib and Dox. Although the
trametinib treated cells and the trametinib plus Dox treated cells were replated at equal cell
numbers, the cloning efficiency of the trametinib plus Dox treated cells was substantially higher
than those treated with trametinib on its own (Figure 5.4B). As a control, we determined that pretreatment with Dox on its own does not improve the cloning efficiency of i-SOX2-T3M4 cells
when replated. In fact, treatment with Dox on its own for 6 days prior to replating in medium
lacking Dox reduces cloning efficiency ~50%. Interestingly, the morphology of the few colonies
formed from the trametinib treated cells continued to exhibit a flattened morphology; whereas the
colonies formed from the trametinib plus Dox treated cells exhibited morphology much closer to
that of untreated i-SOX2-T3M4 cells. In addition, we observed a similar differential in the
number of colonies formed when the trametinib, and trametinib plus Dox treated cells were
replated and grown under anchorage-independent conditions in serum-free, stem cell medium
(Figure 5.4C). Thus, even though elevating SOX2 on its own inhibits the proliferation of i-SOX2T3M4 cells, elevating SOX2 in these cells reduces the growth inhibitory effects of trametinib
under more than one condition.

5.5

Drug Resistant Effects of Elevated SOX2 Are Not Cell Line Specific
To determine whether the protective effects of elevating SOX2 were cell line dependent,
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we examined how elevation of SOX2 influenced the clonal growth of i-SOX2-BxPC3 cells and iSOX2-HPAF-II cells. As in the case of i-SOX2-T3M4 cells, inducible elevation of SOX2 also
reduced the inhibitory effects of trametinib on the clonal growth of i-SOX2-BxPC3 cells and iSOX2-HPAF-II cells (Figure 5.5). For these studies, trametinib was used at the EC50 for iSOX2-BxPC3 cells and i-SOX2-HPAF-II cells (Table 2.1). Thus, the protection afforded by
elevating SOX2 was not limited to i-SOX2-T3M4 cells. Equally important, the protective effect
of SOX2 was not limited to trametinib. Inducible overexpression of SOX2 in i-SOX2-T3M4, iSOX2-BxPC3, and i-SOX2-HPAF-II cells also reduced the inhibitory effects of the AKTi, MK2206 (Figure 5.3, Figure 5.6). Again, MK-2206 was used at the EC50 for each PDAC cell line
(Table 2.1). Altogether, our studies show that although inducible elevation of SOX2 on its own
reduces the clonal growth of three different PDAC cell lines, elevating SOX2 in these cells
partially reverses the growth inhibitory effects of trametinib and MK-2206.

5.6

Knockdown of SOX2 Enhances Growth Inhibitory Effects of MEKi and AKTi
Finally, we examined whether knocking down SOX2 in PDAC cells would lead to further

reduction in growth when the cells were treated with trametinib or MK-2206. Initially, we
addressed this question using i-KdSOX2-T3M4 cells. As in the case of i-SOX2-T3M4 cells,
treatment of i-KdSOX2-T3M4 cells with trametinib or MK-2206 each reduced the number and
the sizes of the colonies that formed when the cells were plated at clonal densities (Figure 5.7A).
Importantly, knocking down SOX2 in conjunction with trametinib or MK-2206 led to a further
reduction in the number of colonies that formed. Like i-KdSOX2-T3M4 cells, growth of iKdSOX2-L3.6 cells at clonal densities was reduced by trametinib and MK-2206 (Figure 5.7B).
Moreover, growth of these cells was reduced even further when SOX2 was knocked down and
the cells were treated with drug. Thus, these findings, in conjunction with the SOX2
overexpression studies described earlier, strongly support the conclusion that SOX2 helps protect
PDAC cells from the growth inhibitory effects of MEKi and AKTi.
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5.7

Summary
Recent work has shown that SOX2 is not only expressed in ~20 different types of human

cancer [12, 125, 129, 130, 132, 141, 148, 149, 151-155, 158-160, 162, 163, 167, 168, 170, 209], it
also appears to influence drug resistance in at least eight of these cancers [129, 137, 141, 142,
151, 152, 154, 158, 163, 168, 169]. SOX2 had been shown to be expressed in PDAC [125, 155],
but its roles in tumor growth and drug resistance had not been examined prior to work described
in this dissertation. In this study, we demonstrate that elevating the levels of SOX2 reduces the
efficacy of several MEKi, including trametinib, and the AKTi MK-2206, which have thus far
yielded disappointing patient responses in PDAC clinical trials. Our studies indicate that the
effects of SOX2 on the responses to trametinib and MK-2206 are not dependent on the mutation
status of KRAS. Going forward, it will be valuable to determine how SOX2 can reduce the action
of MEKi and AKTi. As discussed in Chapter 6, targeting SOX2 or its mode of action could
improve the effectiveness of these drugs against PDAC.
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CHAPTER 6:

Conclusions & Future Directions
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6.1

Overview
The studies presented in this dissertation examined the diverse roles of not only SOX2,

but also the SOX2-associated protein MSI2 in multiple cell types. Previously, our laboratory
performed proteomic screens in ESC, medulloblastoma cells, and glioblastoma cells.
Interestingly, MSI2 interacted with SOX2 in each of these cell types, meriting further study of its
role in ESC and brain tumor cells. We determined that Msi2 is required for ESC, as knockdown
of both Msi2 isoforms induces the differentiation of ESC and reduces their cloning efficiency,
which is not rescued by the overexpression of either Msi2 isoform alone. Furthermore, our studies
of MSI2 in brain tumor cells determined that MSI2 is required for their continued proliferation, as
knockdown of MSI2in DAOY medulloblastoma cells, and in U87 and U118 glioblastoma cells,
dramatically reduces cellular growth.
We extended our study of SOX2 by examining its role in PDAC and found that SOX2 is
necessary for the growth and proliferation of PDAC cells, and that SOX2 functions as a biphasic
molecular rheostat in PDAC, as both small increases and small decreases in SOX2 levels
dramatically alter PDAC growth both in vitro and in vivo. Furthermore, drug resistance of PDAC
tumor cells was altered when SOX2 levels were changed. Elevating SOX2 protected PDAC cells
from the growth inhibitory effects of MEK and AKT inhibitors, but the knockdown of SOX2
enhanced the growth inhibition in the presence of these drugs.
The need for continued study in both of these areas is well established. In the sections
below, the broader outlook and global implications of these studies are examined. Moreover,
future perspectives for carrying this research forward are also presented.

6.2

MSI2 is required for Embryonic Stem Cells and Brain Tumor Cells
The studies presented in Chapter 3 of this dissertation demonstrate that the SOX2-

associated protein MSI2 is a required protein in both ESC and two types of brain tumor cells. In
ESC, we determined that the knockdown of Msi2 disrupts the self-renewal of ESC and induces
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their differentiation. Furthermore, the extent of differentiation and the loss of self-renewal
capacity correlates with the extent to which Msi2 levels were decreased. Remarkably, the
knockdown of Msi2 causes ESC to differentiate despite continued expression of both Sox2 and
Oct4. Similar results were observed in a related study from this laboratory, in which barrier to
autointegration factor 1 (Banf1) was knocked down in human ESC [97]. In that report, human
ESC lost their capacity for self-renewal following Banf1 knockdown even though the localization
and nuclear expression of Sox2 and Oct4 did not change. Thus, it would suggest that the
knockdown of Msi2, like the loss of Banf1, may alter the critical balance of Sox2 and Oct4
relative to other essential proteins required for the self-renewal and pluripotency of ESC, rather
than their absolute levels.
Our studies raise an important question. How does Msi2 regulate the behavior of ESC
and brain tumor cells? Previous studies demonstrate that Msi1 binds to target mRNA transcripts
to prevent their association with the ribosome and other translation machinery [99]. If Msi2
functions through a similar mechanism to block the translation of several critical RNAs, it will be
important to determine which RNAs are targeted. Moreover, it would be interesting to compare
which transcripts Msi2 targets in different cellular contexts, including ESC, hematopoietic stem
cells, brain tumor cells, and additional cancer cell types. Studies of differential RNA expression
following knockdown of MSI2 in brain and other tumor cells could identify critical networks
altered by MSI2 expression. Furthermore, RNA-Seq analyses of the different transcriptomes
would yield insight into molecular mechanisms necessary for the growth of SOX2- and MSI2expressing tumors.
In the future, it will be important to determine whether Msi2 plays a role during
embryogenesis. Although our studies argue that ESC require Msi2, gene ablation studies argue
that Msi2 is not absolutely required for embryogenesis [103, 104]. However, it remains to be
determined whether the reduced frequency of null Msi2 mice is the result of minor defects during
embryogenesis [103, 104]. Moreover, it is possible that Msi1 can compensate for the absence of
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Msi2 during embryogenesis, but is unable to for ESC grown in culture. Thus, much remains to be
discovered regarding the functions and interactions of MSI2 across multiple cell types.

6.3

SOX2 Expression must be maintained at Optimal Levels
Work presented in Chapter 4 of this dissertation demonstrates that SOX2 is clearly

required for the growth of PDAC, as knockdown of SOX2 reduces PDAC growth both in vitro
and in vivo. Furthermore, our studies indicate that endogenous levels of SOX2 in PDAC cells are
optimized for maximum growth, as both increases and decreases in SOX2 reduce PDAC cell
growth. Hence, SOX2 functions as a biphasic molecular rheostat to control PDAC cell
proliferation.
The finding that SOX2 levels need to be maintained at optimal levels was first described
in ES cells, and later in four other tumor types [172]. In ES cells, knockdown of SOX2 or a 2-fold
increase in SOX2 disrupts the self-renewal of ES cells and triggers their differentiation [17]. The
need to maintain SOX2 levels within narrow limits is not surprising when one examines the
SOX2-interactome in different cell types. Proteomic analysis of the SOX2-interactome in ES
cells, as well as medulloblastoma cells and glioblastoma cells, indicates that SOX2 associates in
high molecular weight protein complexes with a large and diverse set of nuclear proteins [80, 93,
210]. In ES cells, SOX2 is part of a highly integrated transcriptional circuitry that involves
multiple master regulators known to control the self-renewal and pluripotency of ESC [93, 95].
Moreover, SOX2 and the other master regulators that it associates with in ES cells each form
complexes with many of the same proteins. As a result, a small increase in the level of SOX2 is
likely to lead to the formation of incomplete protein complexes that are essential for ES cells.
Moreover, the potent biological impact of small changes in SOX2 levels seems all the more likely
because SOX2 forms complexes with a wide variety of proteins involved in many critical cellular
processes. In addition to transcription, SOX2 forms complexes with proteins involved in signal
transduction, DNA repair [80, 93, 210], ubiquitination pathways [80], and RNA binding (MSI2,
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as described in Chapter 3 of this dissertation). Thus, even small disturbances in SOX2 levels can
lead to waves of change throughout multiple signaling networks.

6.4

Strategies for Experimentally Altering SOX2 Levels
Unfortunately, even with abundant evidence pointing to links between SOX2 levels and

tumor growth, there is a lack of consensus regarding the best methods to study changes in SOX2
levels. Some studies outlined in the Introduction report that stable overexpression of SOX2 in
PDAC enhances growth, while the studies described in Chapter 4 indicated that inducible
overexpression of SOX2 in fact reduces growth. The contrasting results obtained studying SOX2
by stable overexpression and inducible overexpression are likely to result from the fundamental
difference in experimental design. Cell lines engineered for inducible overexpression of SOX2
were generated via drug selection of lentiviral transduced cells, which occurred at frequencies
greater than 70%, before SOX2 levels were altered. In direct contrast, cell lines engineered to
stably overexpress SOX2 are subjected to drug selection while SOX2 levels are ectopically
elevated. As a result, any cells that are growth inhibited or grow more slowly due to elevated
levels of SOX2, as we have shown is the case for three different PDAC cell lines, will be lost
during the drug selection period as the faster proliferating cells expand. Consequently, the cells
present in the drug selected population represent only a subpopulation of the parental cells.
Importantly, the studies presented in Chapter 4 of this dissertation argue that this subpopulation is
likely to represent a very small minority of PDAC cells. This is especially clear in the case of iSOX2-T3M4 cells. Continual growth of these cells in the presence of Dox for >10 passages failed
to lead to the emergence of cells that grow faster due to the elevation of SOX2.

6.5

Increases in SOX2 Expression during Tumor Progression must be accompanied by

Compensatory Changes in Other Key Signaling Proteins
It is evident from the studies where SOX2 was elevated from an inducible transgene that
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many, if not nearly all, SOX2-expressing tumor cell lines are growth inhibited when SOX2 is
initially elevated. However, this does not mean that SOX2 expression cannot rise during cancer.
In fact, several lines of evidence argue that increases in the levels of SOX2 undoubtedly occur
during oncogenesis. As discussed earlier, the SOX2 gene is amplified in several cancers [105,
107, 108, 110], and SOX2 has been shown to be expressed in some tumors, but not in their
surrounding tissue. Moreover, in some tumors, SOX2 expression has been shown to increase
during tumor progression [106, 123, 126, 128, 132-134] and high levels of SOX2 correlate with
poor prognosis in many cancers [124, 139, 140, 144, 148]. This raises a fundamental question. If
SOX2 levels must be maintained within optimal limits to promote tumor growth, how can SOX2
levels rise during tumor progression? It is likely that SOX2 must function within the constraints
of its protein-protein interaction network, and therefore increases in the levels of SOX2 must be
accompanied by corresponding changes in the expression of other genes that counterbalance the
growth inhibitory effects of elevated SOX2. Or more specifically, accommodating the increases
in SOX2 expression would require increased expression of genes required for growth promotion
by SOX2 and/or downregulation of genes that interfere with the action of SOX2 when its levels
rise during tumor progression. Clearly, changing SOX2 levels in isolation disrupts cell function.
SOX2 is by no means unique in this regard. Our studies suggest that the effects of SOX2 are
highly context-dependent, similar to other genes, notably TGFβ, which can act as a tumor
suppressor or oncogene. As another example, MAP3K7 and CHD1 have been shown to be codeleted in prostate cancer and their co-deletion in ETS rearrangement-negative prostate cancers
correlates with poor disease-free survival [211]. In a mouse xenograft model of prostate cancer,
knockdown of MAK3K7 on its own had no significant effect on survival, and knockdown of
CHD1 on its own enhanced survival. However, combined knockdown of MAK3K7 and CHD1
led to larger tumor volumes and shorter survival [211]. Accordingly, the identification and
targeting of genes that must change in concert with increases in SOX2 and permit SOX2 to
contribute to tumorigenicity could provide a novel strategy for blocking, or at least, reducing the
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growth of tumors dependent on SOX2.

6.6

Tumor Cells do not Exhibit a Single Optimum for SOX2 Expression
In addition to intracellular changes taking place to balance the increased expression of

SOX2 within individual cells, there may also be a rise in the number of SOX2-positive cells in
the tumor population. Such a shift in the distribution of the tumor cell population may also
contribute to the apparent rise in SOX2 during tumor progression. As shown previously, SOX2
protein levels vary considerably between different PDAC cell lines [155]. In the case of T3M4
and L3.6 PDAC cells, SOX2 expression differs by ~15-fold across cell lines [202]. Furthermore,
we determined by immunofluorescence that SOX2 expression is not distributed evenly among
L3.6 PDAC cells [~10% of the cells endogenously express SOX2 at high levels (SOX2hi), ~30%
at moderate levels, and ~60% at low/undetectable levels (SOX2low), Figure 6.1].Thus, PDAC
cells do not exhibit a single optimum for SOX2 expression. If SOX2 is required for the tumorinitiating/cancer stem cell population, which is the case for at some, if not most SOX2-expressing
cancers, the proportion of SOX2-positive cells in the tumor may rise as the population of tumorinitiating cells increases during tumor progression. Correspondingly, increases in a SOX2positive tumor-initiating cell population would account for the decreased survival and worse
prognosis seen in many SOX2-expressing patient tumors [124, 133, 137-145].

6.7

SOX2 as a Potential Tumor-Initiating Cell Marker
The close examination of current literature presented in the Introduction revealed that

SOX2 is expressed in over 20 different tumors. Importantly, of these SOX2-positive tumors, most
studies have concluded from indirect evidence that SOX2 positive cells are likely to represent the
tumor-initiating cell population of these tumors. However, the only direct evidence for the role of
SOX2 in the tumor-initiating cell population has only been obtained recently using the limiting
cell dilution tumor assay [142, 161-166]. The limiting cell dilution tumor assay measures the
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minimum number of tumor cells needed to reform a tumor when transplanted into a suitable host
and, thus, is the gold standard for measuring the frequency of tumor-initiating cells in the tumor.
An increase in the percentage of tumor-initiating cells would result in fewer cells necessary to
form the tumor. In pancreatic cancer, for example, others have attempted to identify pancreatic
tumor-initiating cells using markers such as CD133, CD44, CD24, ESA, and ALDH1 [212-219].
For example, ALDH+ cells have shown enhanced clonigenic growth in vitro and in vivo [216219], and studies performed by others argue that 10-15% of pancreatic cancer cells grown in
culture are ALDH+ [215]. However, these markers are controversial for PDAC [220]. Studies in
our laboratory with CD133 have shown that when isolated CD133- glioblastoma cells are grown
in culture, CD133 expression rapidly reappears [172]. In addition, we have observed similar
results with the reappearance of ALDH1 positive cells from ALDH1 negative PDAC cells
(Wilder and Rizzino, unpublished results). Future studies will need to consider whether SOX2
may also be a potential PDAC tumor-initiating cell marker, and determine whether SOX2 is coexpressed with these other markers previously reported to associate with PDAC tumor-initiating
cells.
Although SOX2 has been shown to be essential for the tumor-initiating cells of several
other tumors, the roles of SOX2 in the tumor-initiating population of PDAC have not been
determined in vivo. Knockin of GFP-SOX2 into the endogenous SOX2 locus using CRISPR
technology may be the best means to study the role of SOX2 in PDAC tumor-initiating cells.
Gene editing studies like this would enable the fractionation of PDAC cells on the basis of
endogenous SOX2 expression and the isolation of viable SOX2hi and SOX2low cells via
differential GFP expression. Using the isolated cells, one could determine whether the SOX2hi
PDAC population exhibits a higher percentage of tumor-initiating cells than the unsorted or the
SOX2low cell population by performing limiting tumor cell dilution assays. These isolated SOX2hi
and SOX2low cells could then be further examined for expression of markers previously shown to
be associated with PDAC tumor-initiating cells, as well as critical signaling networks in SOX2hi
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and SOX2low PDAC cell subpopulations. A recent study has shown that elevating SOX2 in PaTu8988t cells leads to the expression of CD133, CD44, and AKDH1, all are markers reported by
others to be associated with PDAC tumor-initiating cells [155]. However, controversy surrounds
these markers in the case of PDAC [220]. Co-expression of SOX2 with one or more of these
markers may be a more reliable means of identifying the tumor-initiating cell population. Going
forward, a better understanding of the networks used by SOX2 to influence the tumor-initiating
cells in PDAC may allow future clinical trials to more accurately and reliably treat PDAC tumors
that have elevated SOX2 expression.

6.8

Elevated SOX2 may contribute to a Quiescent Tumor-Initiating Population
In addition to their ability to propagate the tumor, tumor-initiating cells are thought to be

responsible for dormant/quiescent population, [217] but this property is rarely examined.
Quiescent cells can be identified by thymidine analog label retention; these “label-retaining cells”
proceed through the cell cycle at a greatly reduced frequency, resulting in thymidine analog label
retention [164, 221, 222]. In medulloblastoma, SOX2+ cells have been shown to acquire the
labeled thymidine analog more slowly, as well as retain the label following pulse chase
experiments [164]. Furthermore, a recent study in bladder cancer has shown that the quiescent
label-retaining cancer stem cell population does not respond to cytotoxic therapy and is capable
of repopulating the tumor following drug removal [221]. Going forward, it will be important to
determine whether elevation of SOX2 during advanced stages of PDAC affects its tumorinitiating population as well as the treatment options for this highly deadly cancer, in particular
the response of PDAC to specific classes of drugs currently being tested clinically. It may be
possible that the SOX2hi cells of the tumor remain in or enter a quiescent state during
chemotherapeutic treatment, which are often designed to target the rapidly dividing cells of the
tumor. In this way, upon removal of drug treatment the SOX2hi cells may be the first cells primed
and ready to re-enter the cell cycle and begin to repopulate the tumor. Understanding this
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interplay between SOX2 and tumor cell quiescence will undoubtedly be important for the
improved response of pancreatic tumors to current therapeutics.

6.9

Inducible Modulation of SOX2 Levels Alters the Efficacy of Drugs Used Clinically
Multiple studies have shown that SOX2 also influences responses of tumor cells to other

drugs used clinically [129, 130, 141, 154, 158, 163, 168, 169]. Chapter 5 of this dissertation
demonstrates for the first time that inducible elevation of SOX2 in three PDAC cell lines leads to
a reduction in the efficacy of several MEKi, including trametinib, and the AKTi MK-2206. This
is particularly interesting for two reasons. First, elevation of SOX2 on its own inhibits growth,
but when SOX2 is elevated it reduces the efficacy of MEKi and AKTi. Thus, the protective
effects of SOX2 against these drugs are not coupled mechanistically with the effects of SOX2 on
PDAC growth. Going forward, it will be valuable to determine how SOX2 can reduce the action
of MEKi and AKTi. Second, knockdown of SOX2 in PDAC cells combined with drug treatment
leads to further reductions in PDAC cell growth. Consequently, SOX2 appears to be a potential
therapeutic target for improving the treatment of patients with SOX2-positive PDAC. Although it
is generally believed that it is very difficult to develop drugs that directly interfere with the action
of transcription factors, it may be practical to identify small molecule inhibitors that reduce SOX2
gene expression, block the downstream mechanisms by which SOX2 reduces efficacy of MEKi
and AKTi, or, as discussed earlier, target genes that work in concert with SOX2 to promote tumor
growth. In this way, targeting SOX2 or its mode of action could improve the effectiveness of
these drugs against PDAC.
While the studies presented in Chapter 5 have focused largely on the drug resistance of
PDAC cells to MEKi and AKTi, going forward it remains to be determined how SOX2 may or
may not protect PDAC cells from additional chemotherapeutics. Current treatment regimens
include gemcitabine, a regimen combining fluorouracil, irinotecan, oxaliplatin, and leucovorin
(called FOLFIRINOX), and another combining albumin-bound paclitaxel with gemcitabine;
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however these strategies have done little to improve patient survival beyond a few months. The
possibility remains that SOX2 does not selectively protect PDAC cells from only MEKi and
AKTi. It will be important in future studies to evaluate whether SOX2 can also protect PDAC
cells from current standards of care. Cells engineered for sorting based on endogenous SOX2
expression as described above would be particularly useful in this regard, as one could examine
drug resistance to current therapeutics on cells with different levels endogenous SOX2
expression. These types of experiments could greatly enhance our understanding of SOX2 in drug
resistant PDAC cells.
Currently, it is unknown how SOX2 reduces the effectiveness of chemotherapeutics in
PDAC cells. However, progress has been made in understanding how SOX2 is regulated in
PDAC as well has how SOX2 influences the growth of PDAC cells. A recent study points to an
interesting connection between SOX2 and NFATc1. Knockdown of NFATc1, which is often
overexpressed in PDAC, leads to a decrease in SOX2 expression, and this appears to be due to a
direct effect of NFATc1 on SOX2 transcription [223]. In other studies, stable overexpression of
SOX2 in Patu8988t PDAC cells, which do not express detectable levels of endogenous SOX2,
has been shown to increase expression of Twist, Snail and Slug, while decreasing the expression
of E-Cadherin and ZO-1 [155]. Conversely, knocking down SOX2 in PDAC cells increases the
expression of p21Cip1 and p27Kip1 [155]. Thus, under the control of NFATc1, SOX2 appears to
regulate the expression of genes involved in epithelial-mesenchymal transition and cell cycle
regulation.

6.10

SOX2 may influence Drug Efflux in Tumor-Initiating Cells
In addition to cell cycle control, SOX2 may be using additional means to protect PDAC

cells from the growth inhibitory effects of chemotherapeutics used clinically. As outlined in the
Introduction of this dissertation, SOX2 may be acting to protect tumor cells through antiapoptotic
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signaling or quiescent-like phenotypes [126, 152, 158, 164], or SOX2 may promote drug
resistance through various ATP-binding cassette transporters. For example, ABCG2 has been
shown to be upregulated in the side population TIC [151, 154], has been considered to be an
additional cancer stem cell marker, and additional studies have shown that stable downregulation
of SOX2 via shRNAs decreases ABCG2 [142, 159]. An additional study found that induction of
SOX2 in glioma stem cells promotes the expression of ABCC3 and ABCC6 transporters [158].
Furthermore, recent RNA-Seq from our laboratory identified 2 additional ATP-binding cassette
transporters, ABCB6 and ABCC4, which increased >50% and over 5-fold, respectively, when
SOX2 was elevated in PDAC cells. It is possible that SOX2 may be controlling the expression of
these cell surface transporters on tumor cells to influence the efflux of drugs. Recognizing and
focusing on the role of SOX2 in drug resistance could greatly improve the treatment options for
patients with a multitude of cancers, especially those with highly refractory tumors, as the ability
to eradicate the TIC population is likely to be the only way to prevent recurrence.

6.11

Summary
In conclusion, SOX2 clearly plays critical roles in multiple cancers, including PDAC.

SOX2 not only influences tumor growth in these cases, but also influences the responses of
tumors to drugs used clinically. Thus continued study of SOX2 in PDAC and other cancers is
clearly warranted, and could lead to major advancements desperately needed for these highly
deadly malignancies.
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